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CHAPTER I 
 
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF GPR55 AGONISTS 
 
1.1 Introduction 
GPR55 is a G protein-coupled receptor that has been recently deorphanized. The 
membrane-bound receptor is highly expressed in the brain, particularly in striatum.1 It is 
also found on cell surfaces of other tissues and cells such as bone marrow,2 neutrophils3 
and spleen.4 It has been established so far that GPR55 is a potential target for treating 
pain,5 osteoporosis2 and cancer.6 
In adjuvant-induced inflammation and partial nerve ligation pain models, GPR55 
knockout mice developed neither inflammatory nor neuropathic mechanical hyperplasia. 
Such findings present this receptor as a potential target for treating both inflammatory 
and neuropathic pain.5 The knockout mice also revealed a role of GPR55 in regulating 
osteoclasts’ number and function based on the finding that the number of inactive 
osteoclasts was higher compared to wild type mice.2 A recent study revealed high 
expression of GPR55 in myenteric colonic neurons and the involvement of the receptor in 
colonic motility, thus adding to its already established medical applications, the potential 
of treating illnesses linked to colon motility.7 Furthermore, Lysophosphatidyl inositol 
(LPI, 1.1, Figure 1.1), which is the endogenous ligand of GPR55, was demonstrated to 
induce wound healing of human lung endothelial cells and inhibit platelet aggregation.8
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Figure 1.1 Chemical structures of LPI (1.1), CID1792197 (1.2), CID1172084 (1.3) and 
CID2440433 (1.4). 
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The role of GPR55 in cancer proliferation has been recently well-established to be 
proliferative rather than anti-proliferative.6 Not only it was detected in various cancer 
cell lines such as breast, brain, skin6, and prostate9 but also discovered in a number of 
clinical isolates from cancer patients.6 Furthermore, it has been shown that GPR55 
activation stimulates angiogenesis10 and migration9 which explains the correlation of 
GPR55 expression with cancer aggressiveness. The preceding findings present GPR55 as 
an intriguing target for singular treatment of cancer. Its sole use will minimize the side 
effects accompanying the trivial adjuvant therapies used, which necessitates halting 
cancer proliferation, angiogenesis and migration combined for successful cancer 
eradication. 
Initial in vitro screening classified GPR55 as a cannabinoid receptor due to 
similarities with cannabinoid receptors CB1 and CB2.11 Yet the variant cannabinoid 
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ligands exert either different or mainly opposite pharmacology when bound to GPR55. 
AM251 (1.5) (Figure 1.2) for instance, which is a CB1 antagonist, strongly activates 
GPR55.12 Another example is the CB1 and CB2 agonist CP5594013 (1.6) (Figure 1.2) 
which acts as an antagonist when bound to GPR55. In addition, the results obtained for 
the same ligand tested may vary depending on the assay employed and the cell type. For 
example, Rimonabant (1.7) (Figure 1.2) is reported as an agonist14 and an antagonist15 for 
GPR55 using β Arrestin2-GFP assay and ERK1/2 kinase assay, respectively. The 
unpredicted activity for some of the cannabinoid ligands and the unexplainable dual 
activity can be better understood with radiolabeling. Binding assays for a radiolabeled 
potent ligand will provide a proof of pairing and affinity of the ligand with the artificially 
expressed receptor in cell lines and specify the activity of antagonists.16 Also, these 
assays will help in defining a concise classification and understanding of the 
physiological and pharmacological roles of this receptor.  
 
Figure 1.2 Chemical Structures of AM251 (1.5), CP55940 (1.6), Rimonabant (1.7). 
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1.2 Results and Discussion 
LPI (1.1) (Figure 1.1) is not the best candidate to be labeled for studying the receptor 
due to its lack of selectivity to GPR55. The need for such a selective and potent ligand 
prompted high throughput screening which was conducted by the Sanford-Burnham 
screening center. Out of approximately 290,000 different compounds tested, three 
chemically distinct compounds, namely CID1792197 (1.2), CID1172084 (1.3), and 
CID2440433 (1.4) (Figure 1.1), were identified as potent agonists of GPR55 with EC50’s 
of 0.11, 0.16 and 0.26 μM, respectively. An added value to the moderate potency of these 
ligands is their selectivity for GPR55 over other cannabinoid receptors, > 30 μM activity 
of CB1, CB2 and the closely related atypical cannabinoid receptor GPR35, which renders 
them as appropriate leads to develop probes for studying GPR55. 
GPR55 is among the majority of G-protein coupled receptors waiting to be 
crystallized. Attempting to explain the experimental pharmacological behavior of a 
receptor that has not been crystallized is achievable via homology modeling. The 
homology model of GPR55 was designed and constructed using the Beta-2 adrenergic 
receptor as a template. Contrary to class A GPCRs, where the binding pocket is oriented 
horizontally,17 The GPR55 active site, R*, model shows the binding pocket as a deep 
vertical channel reaching down to residue N7.46 which constitutes the end of the binding 
pocket. Yet, the horizontal character of the space near the EC loops was retained. When 
compounds 1.1-1.4 were docked in the binding pocket, the primary interactions were 
between the most negative electrostatic region and residue K2.60 which is the only 
charged residue in the proposed GPR55 binding site (Figure 1.3). Indeed, K2.60A 
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mutation led to no detected response upon ligand binding indicating its importance in 
GPR55 activation and signal transduction.  
 
Figure 1.3 LPI 1.1; CID1792197 1.2, CID1172084 1.3, and CID2440433 1.4 - GPR55 R* 
complexes. 
 
 
 
 
For developing a nano molar-potent ligand, CID1792197 (1.2) was chosen as a lead 
for having the lowest EC50 amongst the screened compounds. Modifications of the lead 
(1.2) were targeted at the two termini. The narrowness of the vertical pore of the binding 
pocket, depicted in the GPR55 R* model and supported by the diminished activity of 
CID1172084 (1.3) upon methylating the amide nitrogen, discouraged carrying 
modifications that will alter the size of the lead core. 
The choice of structural modifications at the two termini aimed towards enhancing 
solubility, eliminating the Michael acceptor functionality and most importantly exploring 
additional interactions as depicted when docking the proposed ligands in the GPR55 R* 
model. (Table 1.1) shows the initially proposed ligands. 
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Table 1.1 Structures of Proposed Analogues 1.8-1.16. 
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To study the effect of enhancing solubility, the anisole moiety in the parent 
compound 1.2 was proposed to be replaced with a pyridine, 1.11.  In Analogues 1.13, 
1.11, and 1.12, the anisole acryloyl was quinolone, isoquinoline or naphthalene rings, 
respectively. The purpose of this substitution was to remove the Michael acceptor yet 
keeping the same spatial arrangement between the carbonyl and the left end aromaticity. 
Modeling of the naphthalene analogue 1.12 indicated additional H bond interactions of 
the hydroxyethyl moiety with two different residues at helices 6 and 7 of GPR55 R* 
model. 
Synthesis and biological evaluation of analogues 1.13-1.16 was aimed to explore the 
effect of the varying substituents attached to the sulfonamide nitrogen. Interactions in the 
horizontal binding pocket near the extracellular loops, where those substituents resided 
when docked in the homology model, included hydrogen bonding for compounds 1.13, 
1.14 and 1.15 and aromatic pi-pi stacking for 1.14.18 The EC50’s of the synthesized 
proposed analogues directed later modifications to further explore the structure-activity 
relationships. 
The proposed synthetic scheme presented a feasible way of introducing the 
substituents separately followed by joining the two termini in a single step (Scheme 1.1).  
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The various sulfonamides were prepared by substituting the chloride in p-nitro sulfonyl 
chloride (1.17) with the proper amine.19   The resulting p-nitro sulfonamide was reduced 
into the corresponding amine through catalytic hydrogenation.20  
 
Scheme 1.1 Retrosynthetic Scheme of GPR55 Agonists 
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For analogues having the quinoline 1.10, isoquinoline 1.11 or naphthalene rings 
1.12, the p-amino sulfonamide was coupled with the 10-membered aromatic 
isothiocyanate intermediate, prepared in situ by reacting the acyl chloride with potassium 
isothiocyanate, to give rise to the target GPR55 proposed analogue.21 As for analogues 
with the pyridinyl acrylamide 1.8-1.9 and methoxyphenyl acrylamide 1.13-1.16, the 
synthesis was envisioned by first coupling the p-amino sulfonamide with acryloyl 
isothiocyanate, prepared in situ by reacting acryloyl chloride 1.18 with potassium 
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isothiocyanate, followed by Grubbs cross-metathesis with either 2-vinylpyridine 1.19 or 
1-methoxy-2-vinylbenzene 1.20.  
1.2.1 Synthesis of the alkylphenyl amine precursors 1.21-1.33 
The majority of the amine precursors were commercially available, while the ones 
which were not accessible were synthesized through reductive amination22 (Scheme 1.2).  
Aniline (1.23) was reacted with the different aldehydes 1.21-1.22, 1.28-1.30 to give the 
corresponding imine which was reduced into the target secondary amines using NaHB4.22 
Initially, in the case of isonicotinaldehyde (1.21) and 5-(hydroxymethyl)furan-2-
carbaldehyde (1.22), the resulting imines 1.24-1.25 were purified. For secondary amines 
1.31-1.33, the imine intermediates were reacted with the reducing agent without being 
isolated. 
 
Scheme 1.2 Synthetic scheme for synthesis of alkyl phenyl amines 1.21-1.33. Reagents 
and conditions: (a) aniline (1.23) ethanol, 80 °C (28-56%); (b) i) NaBH4, MeOH ii) HCl 
(52-72%); (c) i) ethanol, 80 °C ii) NaBH4, MeOH iii) HCl (34-96%). 
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1.2.2 Synthesis of 6-(2-((tert-butyldimethylsilyl)oxy)methyl)-2-naphthoic acid 1.40 
and 6-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-naphthoic acid 1.41 
Precursors for of the variant substituents at the left termini of the lead were 
commercially available except for 6-(2-hydroxyethyl)-2-naphthoic acid or its protected 
version. Thus, it was prepared in lab starting with the commercially available methyl 6-
bromo-2-naphthoate (1.34) (Scheme 1.3). Attempts to reduce the ester 1.34 to the 
corresponding aldehyde 1.36, using DIBAL-H23 in a one pot reaction, were not 
successful despite the efforts of maintaining the temperature of the mixture at -78 °C 
throughout the entire reaction time. The only product observed following quenching the 
reaction at variant times was the alcohol 1.35.  A 24 hour reaction time of 1.34 with 1.2 
equivalents of the reducing reagent did not result in complete conversion to the 
corresponding alcohol 1.35. Thus, the number of equivalents of DIBAL-H used was 
increased to 3 to ensure full conversion. The resulting alcohol was initially reoxidized 
using MnO2 in CHCl3 to give the corresponding aldehyde 1.36.24 The low yields 
recovered upon the use of the aforementioned conditions, in particular when scaling up 
the reaction, necessitated the use of the alternative Swern oxidation conditions. The use 
of DMSO and oxalyl chloride followed by Et3N significantly enhanced the yields of 
oxidizing the alcohol 1.35 to the aldehyde 1.36. A Witting reaction, using 
triphenylphosphonium iodide, was conducted to prepare 2-bromo-6-vinylnaphthalene 
1.37 thus adding an extra carbon to the aldehyde 1.36.25 Hydroboration/oxidation of 1.37 
gave the anti-Markovnikov alcohol 1.38.26 Protection of the alcohol 1.38 was done, using 
TBSCl in basic conditions,27 prior to conversion into the corresponding carboxylic acid 
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1.42. Conversion of the aryl bromide 1.40 into the corresponding carboxylic acid 1.42 
was achieved by lithium-halogen exchange using n-butyl lithium followed by purging the 
mixture with CO2 gas.28 The structurally similar precursor 1.35 was also protected and 
converted to the carboxylic acid 1.41 to investigate further the effect of the side chain 
length on activity. 
 
Scheme 1.3 Synthesis of 6-(2-((tert-butyldimethylsilyl)oxy)methyl)-2-naphthoic acid 
(1.41)and 6-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-naphthoic acid (1.42). Reagents and 
conditions: (a) i) 3 eq. DIBAL-H, THF, - 40 °C ii) NH4Cl(aq) (90%); (b) MnO2, CHCl3 
(47%); (c) i) oxalyl chloride, DMSO ii) Et3N (60%); (d) Ph3PCH3I, NaH, THF (65%); (e) 
i) BH3-THF, THF ii) NaOH, H2O2 (77%); (f) TBSCl, DMAP, Et3N (54-84%); (g) i) 
nBuLi, THF ii) CO2  iii) H3O+ (42%). 
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The discouraging lengthy and low yield method for synthesizing 6-(2-hydroxyethyl)-
2-naphthoic acid prompted the search for an alternative more feasible method (Scheme 
1.4). Prior to substituting the bromine in the bromo ester 1.34 with a hydroxyethyl, it was 
hydrolyzed to the corresponding carboxylic acid 5-(hydroxymethyl)furan-2-carbaldehyde 
(1.43) using KOH in methanol. Initially the carboxylic acid (1.43) was treated with more 
than two equivalents of nBuLi followed by ethylene oxide and a Lewis acid. Analysis of 
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the crude reaction mixture indicated that the sole product, detected by 1H NMR, was the 
dehalogenated acid 1.45. The use of NaH to deprotonate the carboxylic acid prior to 
lithium-halogen exchange by nBuLi proved to be successful. Mass analysis of the crude 
mixture indicated the formation of the intended product; however, a similar result was not 
achieved upon scaling up the reaction under the aforementioned conditions.  
Development of the method is still undergoing to ensure applicability on large-scale 
reactions.  
 
Scheme 1.4 Attempted synthesis of 6-(2-hydroxyethyl)-2-naphthoic acid (1.44). Reagents 
and conditions: (a) 3 eq. KOH, MeOH, 40 °C, 48 hours (56%); (b) i) n-BuLi, THF (0.1 
M), -78 °C; ii) ethylene oxide; iii. BF3.Et2O, -78 °C to rt; (c) i) 1.2 eq. NaH, THF (0.1M) 
ii) nBuLi, -78 °C, 3 hr; iii) ethylene oxide; iv) BF3.Et2O. 
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1.2.3 Synthesis of p-nitro and p-aminobenzene sulfonamides 1.46-1.69 
Upon the availability of the primary or secondary amines, they were reacted with p-
nitro sulfonyl chloride (1.17) in basic conditions to give the corresponding p-nitro 
sulfonamides19 1.46-1.57 (Scheme 1.5). Pd-catalyzed hydrogenation was used to reduce 
the nitro group into the corresponding aniline 1.58-1.69.20  
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Scheme 1.5 Synthesis of p-nitro and p-amino benzene sulfonamides. Reagents and 
conditions: (a) R1R2NH, pyridine, CH2Cl2 (5-91%); (b) Pd/C, H2, MeOH (12-92%). 
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1.2.4 Attempted synthesis of compounds 1.2 and 1.8 via cross metathesis 
As proposed, methoxyphenyl acrylamide 1.2 and pyridinyl acrylamide 1.8 analogues 
were approached via cross metathesis of carbamothioylacrylamide intermediate 1.70 with 
2-vinylpyridine (1.17) or 1-methoxy-2-vinylbenzene (1.16), respectively (Scheme 1.6). 
Unfortunately, polymers of 1.16 and 1.17 were the sole products formed as deducted by 
1H NMR analysis. 
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Scheme 1.6 Attempted synthesis of compounds 1.2 and 1.8 via cross metathesis. 
Reagents and conditions: (a) i) KSCN, CH3CN, -10 °C to rt, 3 hours; ii) 1.58 (47%); (b) 
2-vinylpyridine (1.16) or 1-methoxy-2-vinylbenzene (1.17), Hoveyda-Grubbs Catalyst, 
CH2Cl2. 
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1.2.5 Synthesis of analogues 1.2, 1.10-1.13 and 1.71-1.83 
Analogues 1.10 and 1.8 were prepared by coupling of the isothiocyante intermediate, 
derived from the commercially available carboxylic acids, with the synthesized aniline 
1.58 (Scheme 1.7). This success geared the preparation of pyridinyl acrylamide and 
methoxyphenyl acrylamide analogues towards following the aforstated method. Thus, the 
commercially available carboxylic acids; 2-methoxyphenylacrylic acid 1.71, quinoline-3-
carboxylic acid 1.72, quinoline-7-carboxylic acid 1.73 and the synthesized 6-(2-((tert-
butyldimethylsilyl)oxy)methyl)-2-naphthoic acid 1.38 and 6-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-2-naphthoic acid 1.39 were converted into the more active 
acyl chlorides by refluxing with thionyl chloride. The resultant acyl chlorides were 
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converted into the isothiocyanate intermediates, in situ, using potassium thiocyante.21 The 
crude intermediates were reacted with the prepared p-amino sulfonamides to give the 
target analogues (Scheme 1.7). 
 
Scheme 1.7 Synthesis of analogues 1.2, 1.10-1.13 and 1.75-1.87. Reagents and 
conditions: (a) SOCl2, 80 °C, 3 hrs; (b) i) KSCN, CH3CN, -10 °C – r.t., 3 hrs; ii) 24 hrs 
(6-65%). 
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1.11 R1=Ph, R2=CH3, R3=7-quinolinyl
1.12 R1=Ph, R2=CH3, R3=6-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-naphthoyl
1.13 R1=Ph, R2=CH2CH2OH, R3=2-(2'-methoxy)phenyl acrylyl
1.11 R1=CH3, R2=4-Pyridinyl, R3=2-(2'-methoxy)phenyl acrylyl
1.15 R1=Ph, R2=CH2((5'-CH2OH)furyl), R3=2-(2'-methoxy)phenyl acrylyl 
1.16 R1=Ph, R2=H, R3=2-(2'-methoxy)phenyl acrylyl
1.75 R1=Ph, R2=CH3, R3=6-(2-((tert-butyldimethylsilyl)oxy)methyl)-2-naphthoyl
1.76 R1=Ph, R2=CH2CH2OH, R3=7-quinolinyl
1.77 R1=Ph, R2=CH2(4-pyridinyl), R3=2-(2'-methoxy)phenyl acrylyl
1.78 R1=Ph, R2=CH2((5'-CH2OH)furyl), R3=7-quinolinyl
1.79 R1=Ph, R2=CH2(2-phenol), R3=2-(2'-methoxy)phenyl acrylyl
1.80 R1=Ph, R2=CH2(3-phenol), R3=2-(2'-methoxy)phenyl acrylyl
1.81 R1=Ph, R2=CH2(4-phenol), R3=2-(2'-methoxy)phenyl acrylyl 
1.82 R1=H, R2=3-propyl-1H-indole, R3=2-(2'-methoxy)phenyl acrylyl
1.83 R1=H, R2=CH2CH2OH, R3=2-(2'-methoxy)phenyl acrylyl
1.84 R1=H, R2=CH2CHOHCH2OH, R3=2-(2'-methoxy)phenyl acrylyl
1.85 R1=H, R2=3,4,-dimethylisoxazoyl, R3=2-(2'-methoxy)phenyl acrylyl
1.86 R1=Ph, R2=CH2(4-pyridinyl), R3=7-quinolinyl
1.87 R1=Ph, R2=CH2(4-phenol), R3=7-quinolinyl
a b. i)
b. ii) 1.57-1.68,
O N
N
H
S
O O
H2N 1.74
 
15 
 
Efforts to synthesize analogue 1.8 using the procedure presented in Scheme 1.7 were 
not successful. Table 1.2 summarizes the alterations of the method that were attempted.  
To address the insolubility of the acyl chloride in CH3CN, which was believed to arise 
from the interaction of the hydrochloric acid byproduct with the pyridine basic nitrogen, 
bases such as triethylamine (Entry 1) and dimethylaminopyridine (Entry 2) were added. 
None of the bases used helped in solubilizing the intermediate acyl chloride nor resulted 
in formation of the target product as deduced from TLC analysis. Another approach was 
the use of different solvents; namely dimethylformamide (Entry 3) and dimethyl 
sulfoxide (Entry 4) which aided in dissolving the acyl chloride however did not result in 
product formation.  
 
Table 1.2 Conditions for Synthesis of Compound 1.8. 
 
Entry Solvent Base Reaction time Result 
1 CH3CN Et3N 4 hours No reaction 
2 CH3CN DMAP overnight No reaction 
3 DMF N/A overnight No reaction 
4 DMSO N/A overnight No reaction 
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To decrease the possibility of pyridinium salt formation, an alternative electrophilic 
intermediate was prepared (Scheme 1.8). A base was used in the process of creating the 
acid anhydride which theoretically would help in competing with the pyridinyl nitrogen 
for the produced HCl. Similar to the acyl chloride, the anhydride was not purified yet the 
success of its formation was confirmed by thin layer chromatography.  Nevertheless, no 
product was detected after reacting it with potassium thiocyanate. 
 
Scheme 1.8 Attempts for synthesis of compound 1.8. Reagents and conditions: (a) 
(CH3)3CCOCl, Et3N, THF; (b) KSCN, CH3CN. 
 
O
OH
a b
N
O
O
N
O
N
N
C
S
1.88
O
 
 
 
1.3 Biological Assay Results 
The synthesized final compounds were tested for activation of GPR55 using a β-
Arrestin assay except for the indole analogue 1.82 due to decomposition during 
purification using column chromatography. The stable and strong binding of β-Arrestin, 
labeled with green fluorescent protein, with GPCRs allow an accurate and reproducible 
read out of the activation response.29 The EC50’s are summarized in Figure1.4. The 
synthesized parent ligand activity when retested was significantly decreased (7.0 μM) in 
comparison to the reported activity (0.11 μM) of the same ligand that was prepared by 
another lab. This may indicate that the activities of the synthesized ligands herein are 
significantly more potent than the IC50’s indicate. Despite the difference between the two 
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reported absolute activities of the parent ligand, considerable structure-activity 
relationship can be inferred from the relative activities of the synthesized ligands and this 
will drive future design towards the synthesis of the target single digit nM-active ligand.  
 
Figure 1.4 Biological data for synthesized potential GPR55 agonists. 
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For analogues having the 2-methoxyphenyl acryloyl moiety 1.10, 1.73, 1.75-1.77, 
1.79-1.81, it is crucial for the pharmacophore to have an aromatic phenyl ring as one of 
the substituents of the sulfonamide’s nitrogen; removing the phenyl ring diminished the 
activity. Such an effect can be inferred from the loss of activity when the sulfonamide 
phenyl substituent in compound 1.10 was replaced with hydrogen in compound 1.79. 
Even replacing the phenyl 1.13 with another aromatic bioisostere; namely 3,4-
dimethylisoxazole 1.78, led to the same result as when removing the ring.  Although, the 
aforementioned substituent leads to solubility enhancement, the change of distribution 
and overall electron density of the isoxazole π-system relative to the phenyl counterpart 
may play a major contributing factor to disturbing the pi-pi stacking with the nearby 
interacting residue in the extracellular horizontal part of the binding pocket. 
Among all of the proposed and synthesized analogues, compound 1.12, which has a 
phenyl and a 2’-hydroxyfuran substituents on the sulfonamide nitrogen, showed the best 
activity with an EC50 of 0.12 μM. When compared to 1.10, the rigidity caused by the 
aromatic furan thus positioning the hydroxymethyl in proximity to a hydrogen bond 
donor or acceptor in the horizontal part of the binding pocket can be considered a 
contributing factor in the nearly 6-fold increase in activity. This legitimate assumption 
has driven the choice of making a phenol isostere of the hydroxymethylfuran. To further 
explore the effect of the hydroxyl position in the phenol substituent relative to the 
methylene, ortho 1.79, meta 1.80 and para 1.81 analogues were prepared.  The para-
phenol analogue 1.81 was the most active compared to the ortho 1.79 and meta 1.80, yet 
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it was 4-fold less active than 1.15 suggesting that the furan oxygen may play a part in 
providing additional interactions with the receptor. 
Replacing the 2-methoxyphenyl acryloyl moiety in 1.2 with 3-quinoline and 7-
isoquinoline showed immense difference in activity. The former analogue 1.7 was 
inactive while the 7-quinoline structural isomer 1.10 was moderately active with an EC50 
of 1.0 μM. Such a difference indicates that the nitrogen position in the 10-membered 
heteroaromatic ring is crucial for its interaction with the binding pocket. The 2-
methoxyphenyl acryloyl, in analogues showing activities better than 1.0 μM, was 
substituted with 7-isoquinoline to synergize the relative increase in activity by the two 
termini’s most active substitution. Nevertheless, the outcome of such combinations did 
not follow the same pattern. For some, there was an increase in activity when the 2-
methoxyphenyl acryloyl was substituted with 7-quinoline as seen when comparing 1.81 
to 1.86, while a decrease in activity for the most potent analogue 1.12 was noticed. 
The expected increase in activity in analogue 1.8 was confirmed by the experimental 
moderate activity. As designed, a side chain length of 2 carbons is needed for the 
hydroxyl to reach deep in the base of the binding pocket for its target interaction. This 
can be confirmed by the order of magnitude decrease in activity when shortening the side 
chain by one carbon as in analogue 1.84. Future analogues bearing the 
hydroxyethylnaphthyl group are to be synthesized to enhance the potency further.  
1.4 Experimental  
 Unless otherwise stated, all reactions were carried out under an atmosphere of dry 
nitrogen in oven-dried glassware. Indicated reaction temperatures refer to those of the 
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reaction bath, while room temperature (rt) is noted as 25 °C. All solvents and reagents 
were obtained from commercial sources and were used as received. Analytical thin layer 
chromatography (TLC) was performed on silica gel 60 F254 precoated plates (0.25 mm) 
from Merck. Visualization was accomplished by irradiation under a 254 nm UV lamp. 
Silicycle silica gel 230−400 (particle size 40−63 μm) mesh was used for all flash column 
chromatography. If needed, products were purified by reverse phase chromatography, 
which was performed using a Varian purification system employing a Phenomenex 
Gemini-NX, (5 µm, C18, 110A, AX. 250 × 21.20 mm). The mobile phase was a mixture 
of acetonitrile and H2O containing 0.1% formic acid. 1H NMR spectra were recorded on a 
Jeol ECA 500 MHz spectrometer or a Jeol ECS 400 MHz spectrometer in the solvent 
indicated. All 1H NMR experiments were run at 17 °C except for DMSO-d6 solvent that 
was run at 25 °C. Chemical shifts are reported in δ units, parts per million (ppm) 
downfield of TMS, and were measured relative to the signals for chloroform (7.26 ppm), 
methanol (3.31 ppm), acetone (2.05 ppm) and dimethyl sulfoxide (2.50 ppm). All 13C 
NMR spectra were reported in ppm relative to the signals for chloroform (77 ppm), 
methanol (49 ppm), acetone (29.8 ppm) and dimethyl sulfoxide (39.5 ppm) with 1H 
decoupled observation. Data for 1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, 
sept = septet, oct = octet, m = multiplet), integration and coupling constant (Hz), whereas 
13C NMR analyses were reported in terms of chemical shift and number of equivalent 
carbons if more than one. High resolution mass spectrometry data (HRMS) were 
performed on a Thermo Fisher Scientific UPLC/LTQ Orbitrap XL system.   
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1.4.1 General procedure A for synthesis of secondary amines (1.24-1.25).  
Step 1: Synthesis of Imines 1.21-1.22.30  Aniline (1.23) (1 eq.) and the aldehyde 
1.21-1.22 (1 eq.) were dissolved in dry ethanol (0.5 M) and the resulting mixture heated 
under reflux for 3 hrs. The solution was cooled to room temperature and the solvent 
removed under reduced pressure. Purification of the product was done via 
recrystallization using an appropriate mixture of solvents where enough volume of the 
more polar solvent was added to dissolve the crude mixture and the less polar solvent was 
added until reaching the saturation point. 
(E)-N-Phenyl-1-(pyridin-4-yl)methanimine (1.24).22 The crude product was 
recrystallized using a mixture of ethyl acetate and hexane. Yield (0.936 g, 28%). 1H 
NMR matched that previously reported.22  
1H NMR (500 MHz, Acetone-d6): δ 8.73 (dd, J = 1.7, 4.3 Hz, 2H; Ar-H), 8.64 (s, 1H; 
CH), 7.84 (dd, J = 1.7, 4.3 Hz, 2H; Ar-H), 7.42 (dd, J = 1.7, 6.6 Hz, 2 H; Ar-H), 7.26-
7.30 (m, 3H; Ar-H). 
N
N
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Figure 1.5 1H NMR spectrum of compound 1.24 [500 MHz, Acetone-d6]. 
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(E)-(5-((Phenylimino)methyl)furan-2-yl)methanol (1.25). The crude product was 
recrystallized using a mixture of dichloromethane and hexane. Yield (0.47 g, 56%).  
1H NMR (500 MHz, Acetone-d6): δ 8.33 (s, 1H, N=CH), 7.37 (m, 2H; Ar-H), 7.20 (m, 
3H; Ar-H), 7.00 (d, J = 3.3 Hz, Ar-H), 6.48 (d, J = 3.4 Hz, Ar-H), 4.61 (s, 1H, O-CH2), 
4.60 (s, 1H, O-CH2).  
13C NMR (125 MHz, Acetone-d6): δ 159.3, 152.0, 147.9, 129.2 (2C), 125.9 (2C), 120.9 
(2C), 117.3, 109.3, 56.6.  
HRMS (ESI, m/z): Calculated for C12H12NO2 [M + H]+ 202.0863; found 202.0855 (3.7 
ppm). 
NO
HO
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Figure 1.6 1H and 13C NMR spectra of compound 1.25 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
 
 
 
 
Step 2: Reduction of Imines 1.26-1.27.22 The imine 1.24-1.25 (1 eq.) was dissolved 
in MeOH (0.5 M). NaBH4 (5 eq.) was added portion-wise and the mixture stirred for 24 
hours at room temperature. It was acidified to a pH of 3 using HCl (50 % v/v) followed 
by increasing the pH to 9 using NaOH (2 M). The product was extracted using 
dichloromethane. The organic layer was dried over MgSO4, filtered and concentrated 
under reduced pressure. Purification of the product was done via recrystallization using 
flash column chromatography or an appropriate mixture of solvents where enough 
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volume of the more polar solvent was added to dissolve the crude mixture and the less 
polar solvent was added until reaching the saturation point.  
N-(Pyridin-4-ylmethyl)aniline (1.26). The crude product was recrystallized using a 
mixture of dichloromethane and hexane. Yield (0.786 g, 52%). 1H NMR matched that 
previously reported.22 
1H NMR (500 MHz, Acetone-d6): δ 8.46 (dd, J = 1.7, 4.6 Hz, 2H; Ar-H), 7.33 (dd, J = 
1.7, 4.6 Hz, 2H; Ar-H), 7.04 (dd, J = 1.7, 6.6 Hz, 2H; Ar-H), 6.54-6.59 (m, 3H; Ar-H), 
4.39 (d, J = 5.7 Hz, 2H, CH2). 
N H
N
 
Figure 1.7 1H NMR spectrum of compound 1.26 [500 MHz, Acetone-d6]. 
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(5-((Phenylamino)methyl)furan-2-yl)methanol (1.27). The crude product was purified 
using flash column chromatography over silica gel. It eluted with ethyl acetate and 
hexane (0.2:1, v/v). Yield (0.514 g, 72%).  
1H NMR (500 MHz, Acetone-d6): δ 7.07 (dd, J = 7.2, 8.6 Hz, 2H, Ar-H), 6.68 (dd,  J = 
1.2, 8.6 Hz, 2H, Ar-H), 6.58 (d, J = 7.2  Hz, Ar-H), 6.16 (d, J = 3.2 Hz, 1H, Fu-H), 6.15 
(d, J = 3.2 Hz, 1H, Fu-H), 5.28 (bs, 1H; N-H), 4.44 (d, J = 5.7 Hz, 2H; O-CH2), 4.25 (d, J 
= 5.7 Hz, 2H; N-CH2), 4.21 (t, J = 6.0 Hz, 1H; O-H).  
13C NMR (125 MHz, Acetone-d6): δ 154.8, 153.0, 148.6, 128.9 (2C), 116.8, 112.7 (2C), 
107.6, 107.4, 56.5, 40.7.  
HRMS (ESI, m/z): Calculated for C12H14NO2 [M + H]+ 204.1019; found 204.1014 (2.5 
ppm). 
H
NO
HO
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Figure 1.8 1H and 13C NMR spectra of compound 1.27 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6] 
 
 
 
 
1.4.2 General procedure B for synthesis of secondary amines (1.31-1.34).  
Aniline 1.20 (1 eq.) and the aldehyde 1.25-1.27 (1 eq.) were dissolved in dry ethanol 
(0.8 M) and the resulting mixture heated under reflux for 3 hrs. The solution was cooled 
to room temperature, NaBH4 (5 eq.) added portion-wise and the mixture stirred for an 
hour. It was diluted with H2O and extracted with ethyl acetate. The organic layer was 
dried over MgSO4, filtered and concentrated. Purification of the crude product was 
accomplished via recrystallization using an appropriate mixture of solvents where enough 
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volume of the more polar solvent was added to dissolve the crude mixture and the less 
polar solvent was added until reaching the saturation point. 
2-((Phenylamino)methyl)phenol (1.31). The crude product was via recrystallization 
using a mixture of ethyl acetate and hexane. Yield (0.359 g, 96%). 1H NMR matched that 
previously reported.31 
1H NMR (400 MHz, Chloroform-d3): δ 8.44 (bs, 1H; O-H), 7.26-7.20 (m, 3H; Ar-H), 
7.16 (d. J = 6.9 Hz, 1H; Ar-H), 6.94-6.84 (m, 5H; Ar-H), 4.41 (s, 2H, N-CH2), 3.95 (bs, 
1H; N-H). 1H NMR matched that previously reported.31 
H
N
OH  
Figure 1.9 1H NMR spectrum of compound 1.31 [400 MHz, Chloroform-d3]. 
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3-((Phenylamino)methyl)phenol (1.32). The crude product was purified via 
recrystallization using a mixture of ethyl acetate and hexane. Yield (0.116 g, 36%). 1H 
NMR matched that previously reported.32  
1H NMR (400 MHz, Methanol-d4): δ 7.08 (t, J = 7.8 Hz, 1H; Ar-H), 7.03 (t, J = 8.0 Hz, 
2H; Ar-H), 8.24 (m, 2H; Ar-H), 6.62-6.53 (m, 4H; Ar-H), 4.20 (s, 2H, N-CH2). 
H
N
HO
 
Figure 1.10 1H NMR spectrum of compound 1.32 [400 MHz, Methanol-d4] 
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4-((Phenylamino)methyl)phenol (1.33). The crude product was purified via 
recrystallization using a mixture of ethyl acetate and hexane. Yield (110 mg, 34%). 1H 
NMR matched that previously reported.33 
1H NMR (500 MHz, Chloroform-d3): δ 7.24 (d, J = 8.6 Hz, 2H; Ar-H), 7.17 (dd, J = 7.5, 
8.6 Hz, 2H, Ar-H), 6.80 (d, J = 8.6 Hz, 2H; Ar-H), 6.72 (t, J = 7.5 Hz, 1H; Ar-H), 6.63 
(d, J = 8.6 Hz, 2H; Ar-H), 4.24 (s, 2H; N-CH2). 1H NMR matched that previously 
reported.33 
H
N
HO
 
Figure 1.11 1H NMR spectrum of compound 1.33 [500 MHz, Methanol-d4] 
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1.4.3 General Procedure for the synthesis of p-nitro sulfonamides (1.46-1.57).  
A suspension of p-nitrobenzenesulfonyl chloride 1.17 (1.1 eq.), in CH2Cl2 (0.6 
M), was added to a solution of the amine (1 eq.) and pyridine (2 eq.) in CH2Cl2 (0.9 M) 
and the mixture stirred for 24 hours. It was diluted with CH2Cl2 and extracted with 1M 
HCl and 10% NaHCO3. The organic layer was dried and the solvent evaporated. 
Purification was done via flash column chromatography or recrystallization using an 
appropriate solvent or a mixture of solvents where enough volume of the more polar 
solvent was added to dissolve the crude mixture and the less polar solvent was added 
until reaching the saturation point. 
N-Methyl-4-nitro-N-phenylbenzenesulfonamide (1.46). The crude product was 
purified via recrystallization using a mixture of ethyl acetate and hexane. Yield (0.677 g, 
26%). 1H NMR matched that previously reported.34  
1H NMR (500 MHz, Acetone-d6): δ 8.39 (d, J = 8.6 Hz, 2H; Ar-H), 7.80 (d, J = 8.6 Hz, 
2H; Ar-H), 7.35-7.29 (m, 3H; Ar-H), 7.14 (d, J = 8.0 Hz, 2H; Ar-H), 3.25 (s, 3H; N-
CH3).  
O2N
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Figure 1.12 1H NMR spectrum of compound 1.46 [500 MHz, Acetone-d6]. 
 
 
 
 
N-(2-Hydroxyethyl)-4-nitro-N-phenylbenzenesulfonamide (1.47). The crude product 
was purified via recrystallization using ethyl acetate. Yield (0.147 g, 10%).  
1H NMR (500 MHz, Acetone-d6): δ 8.38 (dd, J = 2.3, 9.2 Hz, 2H; Ar-H), 7.88 (d, J = 9.2 
Hz, 2H; Ar-H), 7.35-7.32 (m, 3H; Ar-H), 7.14 (dd, J = 2.3, 6.9 Hz, 2H; Ar-H), 3.91 (t, J 
= 5.7 Hz, 1H; O-H), 3.77 (t, J = 6.3 Hz, 2H; N-CH2), 3.54 (q, J = 5.7 Hz, 2H; O-CH2).  
13C NMR (125 MHz, Acetone-d6): δ 150.3, 144.4, 139.1, 129.3 (2C), 129.2 (2C), 
129.1(2C), 128.4 (2C), 124.3, 59.4, 53.6.  
HRMS (ESI, m/z): Calculated for C14H15N2O5S [M + H]+ 323.0696; found 323.0691 (1.6 
ppm). 
O2N
S
N
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Figure 1.13 1H and 13C NMR spectra of compound 1.47 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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4-Nitro-N-phenyl-N-(pyridin-4-ylmethyl)benzenesulfonamide (1.48). The crude 
product was purified via recrystallization using ethyl acetate. Yield (0.193 g, 38%). 
1H NMR (500 MHz, Acetone-d6): δ 8.45 (d, J = 6.3 Hz, 2H; Ar-H), 8.43 (d, J = 9.2 Hz, 
2H; Ar-H), 7.94 (d, J = 8.6 Hz, 2H; Ar-H), δ 7.31 (d, J = 6.3 Hz, 2H; Ar-H), 7.29-7.25 
(m, 3H, Ar-H), 7.17-7.15 (m, 2H, Ar-H), 4.96 (s, 2H, N-CH2).  
13C NMR (125 MHz, Acetone-d6): δ 150.6, 149.9 (2C), 145.3, 143.7, 138.5, 129.3 (2C), 
129.2 (2C), 128.8 (2C), 128.4, 124.5 (2C), 123.0 (2C), 53.6.  
HRMS (ESI, m/z): Calculated for C18H16N3O4S [M + H]+ 370.0856; found 370.0844 (3.3 
ppm). 
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Figure 1.14 1H and 13C NMR spectra of compound 1.48 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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N-((5-(Hydroxymethyl)furan-2-yl)methyl)-4-nitro-N-phenylbenzenesulfonamide 
(1.49). The crude product was purified via recrystallization using a mixture of ethyl 
acetate in hexane. Yield (9.3 mg, 5%).  
1H NMR (500 MHz, Acetone-d6): δ 8.38 (dd, J = 2.3, 8.6 Hz, 2H; Ar-H), 7.89 (dd, J = 
2.3, 8.6 Hz, 2H, Ar-H), 7.31-7.26 (m, 3H; Ar-H), 7.05 (dd, J = 2.3, 8.0 Hz, 2H; Ar-H), 
6.06 (d, J = 2.9 Hz, 1H; Fu-H), 6.03 (d, J = 2.9 Hz, 1H; Fu-H), 4.88 (s, 2H; N-CH2), 4.36 
(d, J = 5.7 Hz, 2H; N-CH2), 4.21 (t, J = 5.7 Hz, 1H; O-H). 
13C NMR (125 MHz, Acetone-d6): δ 156.1, 150.3, 148.6, 144.7, 138.7, 129.3 (2C), 129.2 
(2C), 129.1 (4C), 128.5, 124.3 (2C), 110.7, 107.5, 56.3, 48.2.  
HRMS (ESI, m/z): Calculated for C18H17N2O6S [M + H]+ 389.0802; found 389.0794 (2.0 
ppm). 
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Figure 1.15 1H and 13C NMR spectra of compound 1.49 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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4-Nitro-N-phenylbenzenesulfonamide (1.50). The crude product was purified via 
recrystallization was done using ethyl acetate. Yield (68 mg, 5%). 1H NMR matched that 
previously reported.34 
1H NMR (500 MHz, Acetone-d6): δ 9.29 (s, 1H; NH), 8.35 (dd, J = 2.3, 8.6 Hz, 2H; Ar-
H), 8.02 (dd, J = 2.3, 8.6 Hz, 2H; Ar-H), 7.28-7.24 (m, 2H; Ar-H), 7.21-7.19 (m, 2H; Ar-
H), 7.12 (tt, J = 1.2, 7.5 Hz, 1H; Ar-H). 1H NMR matched that previously reported.34 
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Figure 1.16 1H NMR spectrum of compound 1.50 [500 MHz, Acetone-d6]. 
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N-Methyl-4-nitro-N-(pyridin-4-yl)benzenesulfonamide (1.51). The crude product was 
purified via flash column chromatography. It eluted with ethyl acetate and hexane 
(0.75:1, v/v). Yield (0.366 g, 34%).  
1H NMR (500 MHz, Acetone-d6): δ 8.49 (dd, J = 1.7, 4.6 Hz, 2H; Ar-H), 8.40 (dd, J = 
2.3, 9.2 Hz, 2H; Ar-H), 7.90 (dd, J = 2.3, 9.2 Hz, 2H; Ar-H), 7.27 (dd, J = 1.7, 4.6 Hz, 
2H; Ar-H), 3.34 (s, 3H; N-CH2).  
13C NMR (125 MHz, Acetone-d6): δ 150.8 (2C), 148.3, 141.93, 141.92, 129.1 (2C), 
124.6 (2C), 118.6 (2C), 36.5.  
HRMS (ESI, m/z): Calculated for C12H12N3O4S [M + H]+ 294.0543; found 294.0539 (1.4 
ppm). 
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Figure 1.17 1H and 13C NMR spectra of compound 1.51 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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N-(2-Hydroxybenzyl)-4-nitro-N-phenylbenzenesulfonamide (1.52). The crude product 
was purified via recrystallization using a mixture of ethyl acetate and hexane. Yield (175 
mg, 91%). 
1H NMR (400 MHz, Chloroform-d3): δ 8.35 (d, J = 8.7 Hz, 2H; Ar-H), 7.88 (d, J = 8.7 
Hz, 2H; Ar-H), 7.32-7.24 (m, 3H; Ar-H), δ 7.15 (dt, Jd = 1.8 Hz, Jt = 7.3 Hz, 1H; Ar-H), 
6.95 (dd, J = 1.8, 8.0 Hz, 2H; Ar-H), 6.72 (dt, Jt = 1.8 Hz, Jd = 7.8 Hz, 1H; Ar-H), 6.68 (t, 
J = 7.8 Hz, 1H; Ar-H), 4.76 (s, 2H; N-CH2).  
13C NMR (100 MHz, Acetone-d6): δ 155.8, 151.1, 145.0, 139.7, 130.8, 129.9 (2C), 129.7 
(2C), 129.6 (2C), 129.6, 128.8, 125.1, 122.7, 120.3, 115.9, 49.9.  
HRMS (ESI, m/z): Calculated for C19H17N2O5S [M + H]+ 385.0853; found 385.0845 (2.0 
ppm). 
O2N
S
N
O O
HO  
 
 
 
 
 
44 
 
Figure 1.18 1H and 13C NMR spectra of compound 1.52 [400 MHz for 1H, Chloroform-d3 
and 100 MHz for 13C, Acetone-d6]. 
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N-(3-Hydroxybenzyl)-4-nitro-N-phenylbenzenesulfonamide (1.53). The crude product 
was purified via recrystallization using a mixture of ethyl acetate and hexane. Yield (260 
mg, 67%). 
1H NMR (500 MHz, DMSO-d6) δ. 9.35 (bs, 1H; Ar-OH), 8.38 (d, J = 8.6 Hz, 2H; Ar-H), 
7.87 (d, J = 8.6 Hz, 2H; Ar-H), 7.27-7.21 (m, 3H; Ar-H), 7.05 (d, J = 7.5 Hz, 2H; Ar-H), 
7.00 (dd, J = 7.5, 8.0 Hz, 1H; Ar-H), 6.68 (s, 1H; Ar-H), 6.60 (d, J = 7.5 Hz, 1H; Ar-H), 
6.56 (d, J = 8.0 Hz, 1H; Ar-H), 4.73 (s, 2H; N-CH2).  
13C NMR (125 MHz, DMSO-d6) δ. 157.9, 150.5, 143.8, 138.6, 137.7, 129.9, 129.6 (2C), 
129.5 (2C), 129.1 (2C), 128.6, 125.2 (2C), 119.2, 115.4, 115.1, 54.4.  
HRMS (ESI, m/z): calculated for C19H17N2O5S [M + H]+ 385.0853; found 385.0843 (2.5 
ppm). 
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Figure 1.19 1H and 13C NMR spectra of compound 1.53 [500 MHz for 1H and 125 MHz 
for 13C, DMSO-d6]. 
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N-(4-Hydroxybenzyl)-4-nitro-N-phenylbenzenesulfonamide (1.54). Purification was 
done via flash column chromatography using ethyl acetate in hexane (0.2:1 % v/v).  Yield 
(106 mg, 45%).  
1H NMR (500 MHz, Methanol-d4): δ 8.38 (d, J = 9.2 Hz, 2H; Ar-H), 7.86 (d, J = 9.2 Hz, 
2H; Ar-H), 7.22-7.21 (m, 3H; Ar-H), 6.99 (d, J = 8.6 Hz, 2H; Ar-H), 6.95-6.93 (m, 2H; 
Ar-H), 6.59 (d, J = 8.6 Hz, 2H; Ar-H), 4.71 (s, 2H; N-CH2).  
13C NMR (125 MHz, Methanol-d4) δ 156.9, 150.3, 144.3, 138.3, 129.9 (2C), 129.1 (2C), 
128.8 (2C), 128.7 (2C), 128.0, 126.3, 124.0 (2C), 114.8 (2C), 54.3.  
HRMS (ESI, m/z): Calculated for C19H17N2O5S [M + H]+ 385.0853; found 385.0845 (2.0 
ppm). 
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Figure 1.20 1H and 13C NMR spectra of compound 1.54 [500 MHz for 1H and 125 MHz 
for 13C, Methanol-d4]. 
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N-(2-(1H-Indol-3-yl)ethyl)-4-nitrobenzenesulfonamide (1.55). The crude product was 
purified via flash column chromatography over silica gel. It eluted using ethyl acetate in 
hexane (0.25:1 % v/v). Yield (38 mg, 45%).  
1H NMR (400 MHz, Chloroform-d3): δ 8.10 (dd, J = 2.3, 9.2 Hz, 2H; Ar-H), 8.02 (bs, 
1H; Indole-NH), 7.75 (dd, J = 2.3, 9.2 Hz, 2H; Ar-H), 7.31 (d, J = 8.6 Hz, 2H; Ar-H), 
7.16 (t, J = 7.5 Hz, 1H; Ar-H), 7.02 (d, J = 6.9 Hz, 1H; Ar-H), 6.99-6.98 (m, 1H; Ar-H), 
4.46 (t, J = 5.7 Hz, 1H; SO2N-H), 3.35 (q, J = 6.3 Hz, 2H; N-CH2), 2.96 (t, J = 6.3 Hz, 
2H; Ar-CH2).  
13C NMR (100 MHz, Chloroform-d3): δ 149.7, 145.3, 136.5, 128.0 (2C), 126.6, 124.0 
(2C), 122.7, 122.7, 119.8, 118.4, 11.5, 111.2, 43.1, 25.6.  
HRMS (ESI, m/z): Calculated for C16H16N3O4S [M + H]+ 346.0856; found 346.0851 (1.5 
ppm). 
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Figure 1.21 1H and 13C NMR spectra of compound 1.55 [400 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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N-(2-Hydroxyethyl)-4-nitrobenzenesulfonamide (1.56). Purification was done via 
recrystallization using a mixture of ethyl acetate and hexane. Yield (658 mg, 54%).  
1H NMR (500 MHz, Methanol-d4): δ 8.39 (d, J = 8.6 Hz, 2H; Ar-H), 8.08 (d, J = 8.6 Hz, 
2H; Ar-H), 3.52 (t, J = 5.7 Hz, 2H; O-CH2), 3.00 (t, J = 5.7 Hz, 2H; N-CH2). 
13C NMR (125 MHz, Methanol-d4) δ 150.0, 146.6, 128.1 (2C), 124.1 (2C), 60.5, 45.0. 
HRMS (ESI, m/z): Calculated for C8H11N2O5S [M + H]+ 247.0383; found 247.0379 (1.7 
ppm). 
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Figure 1.22 1H and 13C NMR spectra of compound 1.56 [500 MHz for 1H and 125 MHz 
for 13C, Methanol-d4]. 
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N-(2,3-Dihydroxypropyl)-4-nitrobenzenesulfonamide (1.57). The crude product was 
purified via flash column chromatography over silica gel. It eluted using 70% ethyl 
acetate in hexane. Yield (69 mg, 45%). 1H NMR matched that previously reported.35   
1H NMR (500 MHz, Methanol-d4): δ 8.39 (d, J = 8.6 Hz, 2H; Ar-H), 8.08 (d, J = 8.6 Hz, 
2H; Ar-H), 3.60 (p, J = 5.2 Hz, 1H; O-CH) 3.47-3.41 (m, 2H; O-CH2), 3.07 (dd, J = 5.2, 
13.2 Hz, 1H; N-CH2), 2.86 (dd, J = 6.9, 13.2 Hz, 1H; N-CH2).  
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Figure 1.23 1H NMR spectrum of compound 1.57 [500 MHz, Methanol-d4]. 
 
 
 
 
1.4.4 General procedure for the synthesis of p-amino sulfonamides (1.58-1.69).  
Nitro-substituted benzenesulfonamide 1.46-1.57 was dissolved in MeOH (0.1 M) 
and hydrogenated (1 bar-H2) over 50% w/w palladium on charcoal.  The mixture was 
filtered through a pad of celite and the solvent was evaporated under reduced pressure.  
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Purification was done via flash column chromatography or recrystallized using an 
appropriate solvent or mixture of solvents where enough volume of the more polar 
solvent was added to dissolve the crude mixture and the less polar solvent was added 
until reaching the saturation point.36 
4-Amino-N-methyl-N-phenylbenzenesulfonamide (1.58). The crude product was 
purified via recrystallization using MeOH. Yield (210 mg, 12%). 1H NMR matched that 
previously reported.34  
1H NMR (500 MHz, Acetone-d6) δ 7.29 (d, J = 7.5 Hz, 1H; Ar-H), 7.27 (d, J = 6.9 Hz, 
1H; Ar-H),  7.23-7.20 (m, 1H, Ar-H), 7.16 (d, J = 8.6 Hz, 2H; Ar-H), 7.12 (dd, J = 1.7, 
7.5 Hz, 2H; Ar-H), 6.65 (d, J = 8.6 Hz, 2H; Ar-H), 5.53 (bs, 1H; N-H2), 3.08 (s, 3H, N-
CH3).  
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Figure 1.24 1H NMR spectrum of compound 1.58 [500 MHz, Acetone-d6]. 
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4-Amino-N-(2-hydroxyethyl)-N-phenylbenzenesulfonamide (1.59). The crude product 
was purified via recrystallization using a mixture of ethyl acetate and hexane. Yield (236 
mg, 52%).  
1H NMR (400 MHz, Chloroform-d3): δ 8.01 (d, J = 8.7 Hz, 2H; Ar-H), 7.79 (d, J = 8.7 
Hz, 2H; Ar-H), 7.35-7.34 (m, 3H; Ar-H), 7.11-7.09 (m, 2H; Ar-H), 3.77 (t, J = 5.5 Hz, 
2H; O-CH2), 3.69 (t, J = 5.5 Hz, 2H; O-CH2). 
13C NMR (100 MHz, Chloroform-d3): 154.3, 140.6, 139.0, 129.6 (2C), 129.02 (2C), 
129.00 (2C), 128.7, 123.6 (2C), 60.5, 53.8. 
 HRMS (ESI, m/z): Calculated for C14H16N2O3S [M + H]+ 293.0954; found 293.0946 
(2.9 ppm). 
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Figure 1.25 1H and 13C NMR spectra of compound 1.59 [400 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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4-Amino-N-phenyl-N-(pyridin-4-ylmethyl)benzenesulfonamide (1.60). The crude 
product was purified via recrystallization using ethyl acetate. Yield (71 mg, 32%). 
1H NMR (500 MHz, Acetone-d6): δ 8.42 (dd, J = 1.7, 4.6 Hz, 2H; Ar-H), 7.32-7.30 (m, 
4H; Ar-H), 7.24-7.20 (m, 2H; Ar-H), 7.19-7.16 (m, 1H; Ar-H), 7.16-7.12 (m, J = 2H; Ar-
H), 6.71 (dd, J = 2.3, 8.6 Hz, 2H; Ar-H), 5.62 (bs, 1H; N-H2), 4.81 (s, 2H; N-CH2). 
 13C NMR (125 MHz, Acetone-d6): δ 153.2, 149.8 (2C), 146.3, 139.9, 129.8 (2C), 128.7 
(2C), 128.6 (2C), 127.5, 124.0, 123.1 (2C), 113.1, 52.8.  
HRMS (ESI, m/z): calculated for C18H18N3O2S [M + H]+ 340.1114; found 340.1104 (3.0 
ppm). 
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Figure 1.26 1H and 13C NMR spectra of compound 1.60 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d3]. 
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4-Amino-N-((5-(hydroxymethyl)furan-2-yl)methyl)-N-phenylbenzenesulfonamide 
(1.61). The crude product was purified via flash column chromatography. It eluted using 
ethyl acetate in hexane (0.4:1 % v/v). Yield (253 mg, 50%). 
1H NMR (400 MHz, Chloroform-d3): δ 7.37 (d, J = 8.7 Hz, 2H; Ar-H), 7.25-7.22 (m, 
3H; Ar-H), 7.02-6.99 (m, 2H; Ar-H), δ 6.60 (d, J = 8.7 Hz, 2H; Ar-H), 6.07 (d, J = 3.2 
Hz, 1H; Ar-H), 5.99 (d, J = 3.2 Hz, 1H; Ar-H), 4.69 (s, 2H; O-CH2), 4.44 (s, 2H; N-CH2).  
13C NMR (125 MHz, Acetone-d6): δ 155.5, 153.0, 149.4, 139.8, 129.8 (2C), 128.9 (2C), 
128.6 (2C), 127.6, 124.6, 113.1 (2C), 110.0, 107.6, 56.4, 47.4.  
HRMS (ESI, m/z): Calculated for C18H19N2O4S [M + H]+ 359.1060; found 359.1056 (1.1 
ppm). 
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Figure 1.27 1H and 13C NMR spectra of compound 1.61 [400 MHz for 1H, Chloroform-d3 
and 125 MHz for 13C, Acetone-d3]. 
 
 
 
  
61 
 
4-Amino-N-phenylbenzenesulfonamide (1.62). The crude product was purified via 
recrystallization using methanol. Yield (82 mg, 18%). 1H NMR matched that previously 
reported.34 
1H NMR (500 MHz, Acetone-d6): δ 8.63 (bs, 1H; Ar-NH2), 7.44 (dd, J = 2.3, 8.6 Hz, 2H; 
Ar-H), 7.21-7.16 (m, 4H; Ar-H), 6.99 (tt, J = 1.7, 6.9 Hz, 1H; Ar-H), 6.62 (dd, J = 2.3, 
8.6, 2H; Ar-H), 5.45 (bs, 1H; SO2-NH).  
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Figure 1.28 1H NMR spectrum of compound 1.62 [500 MHz, Acetone-d3]. 
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4-Amino-N-methyl-N-(pyridin-4-yl)benzenesulfonamide (1.63). Yield (0.107g, 73%).  
1H NMR (500 MHz, Acetone-d3): δ 8.42 (dd, J = 1.7, 4.6 Hz, 2H; Ar-H), 7.29 (d, J = 
2.3, 8.6 Hz, 2H; Ar-H), 7.25 (dd, J = 1.7, 4.6 Hz, 2H; Ar-H), 6.66 (d, J = 1.7, 8.6 Hz, 2H; 
Ar-H), 5.65 (d, J = 6.3 Hz, 1H; N-H2), 3.20 (s, 3H; N-CH3).  
13C NMR (125 MHz, Acetone-d6): δ 153.5, 150.2 (2C), 149.3, 129.5 (2C), 122.5, 117.4 
(2C), 113.1, 113.0, 113.0 (2C), 35.7. 
HRMS (ESI, m/z): Calculated for C12H14N3O2S [M + H]+ 264.0801; found 264.0794 (2.7 
ppm). 
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Figure 1.29 1H and 13C NMR spectra of compound 1.63 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d3]. 
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4-Amino-N-(2-hydroxybenzyl)-N-phenylbenzenesulfonamide (1.64). Purification was 
done via flash column chromatography using 30% ethyl acetate in hexane. Yield (70 mg, 
76%).  
1H NMR (400 MHz, Methanol-d4) δ 7.27 (d, J = 8.7 Hz, 2H; Ar-H), 7.19-7.13 (m, 4H; 
Ar-H), 7.02 (dd, J = 1.8, 7.8 Hz, 2H; Ar-H), 6.93 (dt, Jd =1.8 Hz, Jt = 7.8 Hz, 2H; Ar-H), 
6.66-6.59 (m, 4H; Ar-H), 4.72 (s, 2H; N-CH2).  
13C NMR (100 MHz, Acetonitrile-d3) δ: 155.0, 152.8, 139.6, 130.2, 129.8 (2C), 129.0, 
128.7 (2C), 128.6 (2C), 127.7, 124.1, 122.2, 119.8, 115.4, 113.2 (2C), 49.0.  
HRMS (ESI, m/z): Calculated for C19H19N2O3S [M + H]+ 355.1111; found 355.1102 (2.5 
ppm). 
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Figure 1.30 1H and 13C NMR spectra of compound 1.64 [400 MHz for 1H, Methanol-d4 
and 100 MHz for 13C, Acetonitrile-d3]. 
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4-Amino-N-(3-hydroxybenzyl)-N-phenylbenzenesulfonamide (1.65). Purification was 
done via flash column chromatography using 30% ethyl acetate in hexane. Yield (63 mg, 
68%).  
1H NMR (400 MHz, Methanol-d4): δ 7.27 (d, J = 8.7 Hz, 2H; Ar-H), 7.19-7.13 (m, 3H; 
Ar-H), 7.00-6.94 (m, 3H; Ar-H), 6.69 (s, 1H; Ar-H), 6.63 (m, 3H; Ar-H), 6.55 (dd, J = 
1.8, 7.8 Hz, 1H; Ar-H), 4.6 (s, 1H; N-CH2). 
13C NMR (125 MHz, Acetone-d6): δ 157.1, 153.2, 139.5, 138.0, 129.5 (2C), 128.9 (2C), 
128.9 (2C), 128.3, 127.3, 123.8, 119.4, 115.0, 114.0, 112.9, 53.9.  
HRMS (ESI, m/z): Calculated for C19H19N2O3S [M + H]+ 355.1111; found 355.1096 (4.2 
ppm). 
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Figure 1.31 1H and 13C NMR spectra of compound 1.65 [400 MHz for 1H, Methanol-d4 
and 125 MHz for 13C, Acetone-d6]. 
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4-Amino-N-(4-hydroxybenzyl)-N-phenylbenzenesulfonamide (1.66). Purification was 
done via flash column chromatography using 30% ethyl acetate in hexane. Yield (35.5 
mg, 47%).  
1H NMR (400 MHz, Acetonitrile-d3): δ 7.29 (d, J = 8.7 Hz, 2H; Ar-H), 7.22-7.15 (m, 
3H; Ar-H), 7.02-6.97 (m, 4H; Ar-H), 6.83 (s, 1H; Ar-OH), 6.64 (d, J = 8.7 Hz, 2H; Ar-
H), 6.60 (d, J = 8.2 Hz, 2H; Ar-H), 4.85 (bs, 2H; Ar-NH2), 4.57 (s, 2H; N-CH2). 
13C NMR (100 MHz, Acetonitrile-d3): δ 156.3, 152.6, 139.6, 129.9 (2C), 129.7 (2C), 
129.0 (2C), 128.6 (2C), 127.7, 127.5, 124.7, 115.0 (2C), 113.2 (2C), 53.3.  
HRMS (ESI, m/z): Calculated for C19H19N2O3S [M + H]+ 355.1111; found 355.1108 (0.8 
ppm). 
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Figure 1.32 1H and 13C NMR spectra of compound 1.66 [400 MHz for 1H and 100 MHz 
for 13C, Acetonitrile-d3]. 
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N-(2-(1H-Indol-3-yl)ethyl)-4-aminobenzenesulfonamide (1.67). Purification was done 
via flash column chromatography using 50% ethyl acetate in hexane. Yield (56.8 mg, 
41%).  
1H NMR (400 MHz, Methanol-d4): δ 7.48 (d, J = 8.7 Hz, 2H; Ar-H), 7.37 (d, J = 7.8 Hz, 
1H; Ar-H), 7.27 (d, J = 7.8 Hz, 1H; Ar-H), 7.03 (t, J = 7.3 Hz, 1H; Ar-H), 6.95 (s, 1H; 
Ar-H), 6.93 (t, J = 7.8 Hz, 1H; Ar-H), 6.64 (d, J = 8.7 Hz, 2H; Ar-H), 3.05 (dd, J = 7.3, 
7.8 Hz, 2H; N-CH2), 2.82 (dd, J = 7.3, 7.8 Hz, 2H; Ar-CH2).  
13C NMR (100 MHz, Methanol-d4): δ 152.7, 136.7, 128.6 (2C), 127.2, 126.2, 122.2, 
121.0, 118.3, 117.8, 113.1 (2C), 111.4, 110.9, 43.6, 25.4.   
HRMS (ESI, m/z): Calculated for C16H18N3O2S [M + H]+ 316.1114; found 316.1106 (2.6 
ppm). 
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Figure 1.33 1H and 13C NMR spectra of compound 1.67 [400 MHz for 1H and 100 MHz 
for 13C, Methanol-d4]. 
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4-Amino-N-(2-hydroxyethyl)benzenesulfonamide (1.68). Purification was done via 
recrystallization using a mixture of ethyl acetate in hexane. Yield (118 mg, 34%). 
1H NMR (500 MHz, Methanol-d4) δ: δ 7.51 (d, J = 8.6 Hz, 2H; Ar-H), 6.68 (d, J = 8.6 
Hz, 2H; Ar-H), 3.51 (t, J = 5.7 Hz, 2H; O-CH2), 2.87 (t, J = 5.7 Hz, 2H; N-CH2). 
13C NMR (125 MHz, Methanol-d4): δ 152.8, 128.6 (2C), 125.9, 113.1 (2C), 60.5, 44.8. 
HRMS (ESI, m/z): Calculated for C8H13N2O3S [M + H]+ 217.0641; found 217.0637 (2.0 
ppm). 
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Figure 1.34 1H and 13C NMR spectra of compound 1.68 [500 MHz for 1H and 125 MHz 
for 13C, Methanol-d4]. 
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4-Amino-N-(2,3-dihydroxypropyl)benzenesulfonamide (1.69). Purification was done 
via flash column chromatography using 100% ethyl acetate. Yield (47 mg, 92%). 1H 
NMR matched that previously reported.35 
1H NMR (500 MHz, Methanol-d4): δ 7.51 (d, J = 8.6 Hz, 2H; Ar-H), 6.68 (d, J = 8.6 Hz, 
2H; Ar-H), 3.62 (p, J = 5.2 Hz, 1H; CHO), 3.48 (dd, J = 4.6, 11.5 Hz, 1H; O-CH2), 3.43 
(dd, J = 4.6, 11.5 Hz, 1H; O-CH2), 2.91 (dd, J = 5.2, 13.2 Hz, 1H; N-CH2),  2.74 (dd, J = 
5.2, 13.2 Hz, 1H; N-CH2). 
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Figure 1.35 1H and 13C NMR spectra of compound 1.69 [500 MHz, Methanol-d4] 
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1.4.5 Synthesis of 6-(2-((tert-Butyldimethylsilyl)oxy)methyl)-2-naphthoic acid (1.41) 
and 6-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-naphthoic acid (1.42). 
(6-Bromonaphthalen-2-yl)methanol (1.35).23 
     Methyl 6-bromo-2-naphthoate (1.34) (1.5 g, 5.66 mmol) was dissolved in anhydrous 
THF and cooled to -40 °C in CH3CN/dry ice bath. DIBAL-H (17 mL, 17 mmol) was 
added drop wise and the mixture left stirring at ambient temperature for 8 hours. The 
mixture was then quenched using a saturated solution of NH4Cl (15 mL) followed by 
extraction with CH3Cl (100 mL x 2). The organic layers were combined, extracted with 
H2O (100 mLx1), dried using anhydrous Na2SO4 and the solvent evaporated. Yield 
(1.194 g, 90%). 1H NMR matched that previously reported.37 
1H NMR (500 MHz, Acetone-d6) δ 8.07 (d, J = 1.7 Hz, 1H; Ar-H), 7.84-7.79 (m, 3H; Ar-
H), 7.57-7.52 (m, 2H; Ar-H), 4.77 (s, 2H; O-CH2), 4.85 (bs, 1H; O-H).  
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Figure 1.36 1H NMR spectrum of compound 1.35 [500 MHz, Acetone-d6]. 
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6-Bromo-2-naphthaldehyde (1.36).38 DMSO (2.9 mL, 41.2 mmol) was added drop-wise 
to a solution of oxalyl chloride (1.77 mL, 20.58 mmol) in CH2Cl2 (65 mL) at -78 °C. A 
solution of (6-bromonaphthalen-2-yl)methanol (1.35) (1.22 g, 5.14 mmol) in CH2Cl2 (12 
mL) was then added drop-wise and the mixture stirred for 15 minutes. Triethylamine 
(12.9 mL, 0.926 mmol) was then added to mixture drop-wise followed by H2O (5 mL) 
after 15 minutes. The mixture was diluted with EtOAc (100 mL) and extracted with 20 
KHSO3 (100 mLx2) and brine (100 mL). The organic layer was dried and condensed 
under reduced pressure. Yield (724 mg, 60%). 1H NMR matched that previously 
reported.39  
1H NMR (500 MHz, Acetone-d6): δ 10.16 (s, 1H; O=CH), 8.52 (s, 1H; Ar-H), 8.24 (d, J 
= 2.3 Hz, 1H; Ar-H), 8.08 (d, J = 8.6 Hz, 1H; Ar-H), 8.02 (d, J = 8.6 Hz, 1H; Ar-H), 7.96 
(dd, J = 1.2, 8.6 Hz, 1H; Ar-H), 7.74 (dd, J = 1.7, 8.6 Hz, 1H; Ar-H).  
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Figure 1.37 1H NMR spectrum of compound 1.36 [500 MHz, Acetone-d6]. 
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2-Bromo-6-vinylnaphthalene (1.37).25 Sodium hydride (0.299 g, 12.46 mmol) was 
added to a suspension of 6-bromo-2-naphthaldehyde (1.36) (0.586 g, 2.49 mmol) and 
triphenylphosphonium iodide (1.61 g, 3.99 mmol) in anhydrous THF (30 mL) and the 
mixture stirred for 25 hours. The mixture was diluted with CHCl3 (30 mL) and extracted 
with brine (100 mL x 3). The organic layer was dried using anhydrous Na2SO4 and 
condensed under reduced pressure. The solid residue was purified via flash column 
chromatography (5% Ethyl acetate/Hexane) to afford the desired product. Yield (377 mg, 
65%). 1H NMR matched that previously reported.40 
1H NMR (400 MHz, Chloroform-d3): δ 7.95 (d, J = 1.8 Hz, 1H; Ar-H), 7.70-7.63 (m, 
4H; Ar-H), 7.52 (dd, J = 2.3, 8.7 Hz, 1H; Ar-H), 6.84 (dd, J = 11.0, 17.9 Hz, 1H; Ar-
CH=C), 5.86 (d, J = 17.9 Hz, 1H; C=CH2), 5.36 (d, J = 11.0 Hz, 1H; C=CH2). 
Br  
Figure 1.38 1H NMR spectrum of compound 1.37 [400 MHz, Chloroform-d3]. 
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2-(6-Bromonaphthalen-2-yl)ethan-1-ol (1.38).26 2-Bromo-6-vinylnaphthalene (1.37) 
(200 mg, 0.858 mmol) was added to a cooled solution of BH3.THF (0.64 mL, 0.64 mmol) 
in anhydrous THF (4 mL) and the mixture stirred for 2 hours at ambient temperature. 
NaOH (3M, 0.52 mL) followed by 30% H2O2 (0.17 mL) were added and the mixture 
stirred for additional 2 hours. The mixture was then diluted with EtOAc (20 mL), 
extracted with H2O and brine (20 mL x 2), dried over anhydrous Na2SO4) and condensed 
under reduced pressure. The solid residue was purified via flash column chromatography 
(0-60% EtOAc/Hexane) to afford the desired product. Yield (98 mg, 46%). 1H NMR 
matched that previously reported.37 
1H NMR (500 MHz, Chloroform-d3): δ 7.97 (d, J =1.8 Hz, 1H; Ar-H), 7.70 (d, J = 8.6 
Hz, 1H; Ar-H), 7.65 (d, J = 8.7 Hz, 1H; Ar-H), 7.64 (s, 1H; Ar-H), 7.52 (dd, J = 2.3, 8.6 
Hz, 1H; Ar-H),  7.38 (dd, J = 1.7, 8.6 Hz, 1H; Ar-H), 3.94 (t, J = 6.3 Hz, 2H; O-CH2), 
3.00 (t, J = 6.3 Hz, 2H; Ar-CH2).  
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Figure 1.39 1H NMR spectrum of compound 1.38 [500 MHz, Chloroform-d3]. 
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((6-bromonaphthalen-2-yl)methoxy)(tert-butyl)dimethylsilane (1.39).27 tert-
Butyldimethylsilyl chloride (100 mg, 0.42 mmol), 4-dimethylaminopyridine  (12.9 mg, 
0.11 mmol), and trimethylamine (0.22 mL, 0.55 mmol) were added to a solution of 2-(6-
bromonaphthalen-2-yl)methanol (100 mg, 0.42 mmol) in CH2Cl2 (5 mL) and stirred at 
room temperature for 25 hours. The mixture was then diluted with CH2Cl2 (10 mL), 
extracted with a saturated solution of NH4Cl (15 mLx2). The organic layer was dried 
using anhydrous sodium sulfate and condensed under reduced pressure. The solid residue 
was purified via flash column chromatography (0-5% EtOAc/Hexane) to afford the 
desired product. Yield (125 mg, 84%). 1H NMR matched that previously reported.41 
1H NMR (500 MHz, Chloroform-d3): δ 7.97 (s, 1H; Ar-H), 7.74 (s, 1H; Ar-H), 7.70 (t, J 
= 8.2 Hz, 2H; Ar-H), 7.52 (dd, J = 1.8, 8.7 Hz, 1H; Ar-H), 7.44 (d, J = 8.2 Hz, 1H; Ar-
H), 4.87 (s, 2H; O-CH2), 0.97 (s, 9H, Si-C(CH3)3), 0.13 (s, 6H; Si(CH3)2).  
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Figure 1.40 1H NMR spectrum of compound 1.39 [500 MHz, Chloroform-d3]. 
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(2-(6-Bromonaphthalen-2-yl)ethoxy)(tert-butyl)dimethylsilane (1.40).27 tert-
butyldimethylsilyl chloride (57.6 mg, 0.38 mmol), 4-dimethylaminopyridine  (9.7 mg, 
0.08 mmol), and trimethylamine (58 µL, 0.414 mmol) were added to a solution of 2-(6-
bromonaphthalen-2-yl)ethanol 1.5 (80.0 mg, 0.32 mmol) in CH2Cl2 (4 mL) and stirred at 
room temperature for 25 hours. The mixture was then diluted with CH2Cl2 (10 mL, 
extracted with a saturated solution of NH4Cl (15 mLx2). The organic layer was dried 
using anhydrous sodium sulfate and condensed under reduced pressure. The solid residue 
was purified via flash column chromatography (0-5% EtOAc/Hexane) to afford the 
desired product. Yield (62 mg, 53%). 1H NMR matched that previously reported.42 
1H NMR (500 MHz, Chloroform-d3): δ 7.96 (d, J =1.7 Hz, 1H; Ar-H), 7.67 (d, J = 8.6 
Hz, 1H; Ar-H), 7.64 (d, J = 8.6 Hz, 1H; Ar-H), 7.62 (s, 1H; Ar-H), 7.51 (dd, J = 2.3, 8.6 
Hz, 1H; Ar-H), 7.37 (dd, J = 1.7, 8.6 Hz, 1H; Ar-H), 3.87 (t, J = 6.9 Hz, 2H; O-CH2), 
2.96 (t, J = 6.9 Hz, 2H; Ar-CH2), 0.85 (s, 9H, Si-C(CH3)3), -0.05 (s, 6H; Si(CH3)2).  
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Figure 1.41 1H NMR spectrum of compound 1.40 [500 MHz, Chloroform-d3]. 
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6-(2-((tert-butyldimethylsilyl)oxy)methyl)-2-naphthoic acid (1.41).28 A solution of (2-
(6-Bromonaphthalen-2-yl)methoxy)(tert-butyl)dimethylsilane (1.39) (100 mg, 0.29 
mmol) in anhydrous THF (10 mL) was cooled to -78 °C was added drop-wise to a 
previously cooled n-butyllithium (0.12 mL, 0.30 mmol) and the mixture stirred for 3 
hours. The mixture was purged with CO2 gas at -78 °C for half an hour then allowed to 
warm to room temperature. The mixture was then acidified with 1 M HCl, extracted with 
ethyl acetate (20 mL x 2) and the organic layer dried over anhydrous Na2SO4 and 
condensed under reduced pressure. Purification was done via flash column 
chromatography using 20% ethyl acetate in hexane.  Yield (17.0 mg, 19%). 1H NMR 
matched that previously reported.43 
1H NMR (500 MHz, Chloroform-d3): δ 8.67 (bs, 1H; Ar-H), 8.10 (dd, J = 1.7, 8.6 Hz, 
1H; Ar-H), 7.94 (d, J = 8.6 Hz, 1H; Ar-H), 7.89 (d, J = 8.6 Hz, 1H; Ar-H), 7.84 (s, 1H; 
Ar-H), 7.50 (dd, J = 1.2, 8.6 Hz, 1H; Ar-H), 4.93 (s, 2H; O-CH2), 0.98 (s, 9H, Si-
C(CH3)3), 0.14 (s, 6H; Si(CH3)2).  
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Figure 1.42 1H NMR spectrum of compound 1.41 [500 MHz, Chloroform-d3]. 
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6-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-naphthoic acid (1.42).28 A solution of (2-(6-
Bromonaphthalen-2-yl)ethoxy)(tert-butyl)dimethylsilane (1.40)  (61.9 mg, 0.17 mmol) in 
anhydrous THF (4 mL) was cooled to -40 °C was added drop-wise to a previously cooled 
n-butyllithium (0.25 mL, 0.25 mmol) and the mixture stirred for 3 hours. The mixture 
was purged with CO2 gas at -40 °C for half an hour then allowed to warm to room 
temperature. The mixture was then acidified with 1 M HCl, extracted with brine (20 mL 
x 2) and the organic layer dried over anhydrous Na2SO4 and condensed under reduced 
pressure. Purification was done via flash column chromatography using 50% v/v ethyl 
acetate in hexane. Yield (29.7mg, 53%).  
1H NMR (500 MHz, Chloroform-d3): δ 8.67 (bs, 1H; Ar-H), 8.09 (dd, J = 1.7, 8.6 Hz, 
1H; Ar-H), 7.90 (d, J = 8.6 Hz, 1H; Ar-H), 7.84 (d, J = 8.6 Hz, 1H; Ar-H), 7.72 (s, 1H; 
Ar-H), 7.45 (dd, J = 1.7, 8.6 Hz, 1H; Ar-H), 3.91 (t, J = 6.9 Hz, 2H; O-CH2), 3.01 (t, J = 
6.9 Hz, 2H; Ar-CH2), 1.25 (s, 9H, Si-C(CH3)3), 0.86 (s, 6H; Si(CH3)2).  
13C NMR (100 MHz, Methanol-d4): δ 169.3, 139.9, 135.7, 131.4, 130.4, 128.7, 128.5, 
127.9, 127.3, 127.2, 125.2, 63.9, 39.3, 25.0, -6.7.   
HRMS (ESI, m/z): Calculated for C19H27O3Si [M + H]+ 331.1724; found 331.1720 (1.2 
ppm). 
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Figure 1.43 1H and 13C NMR spectra of compound 1.42 [500 MHz for 1H, Chloroform-d3 
and 100 MHz for 13C, Methanol-d4]. 
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6-Bromo-2-naphthoic acid (1.43).44 Potassium hydroxide (127 mg, 2.26 mmol) was 
added to a suspension of methyl 6-bromo-2-naphthoate (200 mg, 0.75 mmol) in methanol 
(50 mL) and the mixture heated at 50 °C for 48 hours. The solvent was evaporated and 
the residue diluted with water (30 mL), acidified with HCl (1M) and the extracted with 
ethyl acetate (30 mL x 2). The combined organic layers were dried with anhydrous 
magnesium sulfate and the solvent evaporated under reduced pressure. The crude product 
was purified via recrystallization using ethyl acetate to give the product as white crystals 
(105 mg, yield 56%). 1H NMR matched that previously reported.45 
1H NMR: (400 MHz, Methanol-d4): δ 8.58 (s, 1H; Ar-H), 8.14 (s, 1H; Ar-H), 8.06 (dd, J 
= 1.8, 8.7 Hz, 1H; Ar-H), 7.92 (d, J = 8.7 Hz, 1H; Ar-H), 7.87 (d, J = 8.7 Hz, 1H; Ar-H), 
7.64 (dd, J = 1.8, 8.7 Hz, 1H; Ar-H). 
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Figure 1.44 1H NMR spectrum of compound 1.43 [400 MHz, Methanol-d4]. 
 
 
 
 
1.4.6 Synthesis of N-((4-(N-methyl-N-
phenylsulfamoyl)phenyl)carbamothioyl)acrylamide (1.70).  
KSCN (48 mg, 0.50 mmol)) was added to a cooled solution of acryloyl chloride 
(0.02 mL, 0.25 mmol) in anhydrous acetonitrile (1mL) and the reaction was allowed to 
stir for 4 hours at room temperature. The solid KCl was removed through filtration and 
aniline 2 (65 mg, 0.25mmol), dissolved in acetonitrile (1 mL), was added drop wise to the 
filtrate and the mixture stirred for 24 hours and the solvent evaporated. The crude product 
was purified via frit column chromatography using 50% ethyl acetate in hexane to give a 
white solid (44 mg, yield 47%). 
 1H NMR (500 MHz, Chloroform-d3): δ 12.83 (s, 1H; N-H), 8.76 (s, 1H; N-H), 7.90 (d, J 
= 8.4 Hz, 2H; Ar-H), 7.56 (d, J = 8.4 Hz, 2H; Ar-H), 7.32-7.27 (m, 3H; Ar-H), 7.10 (d, J 
= 8.4 Hz, 2H; Ar-H), 6.60 (d, J = 16.8 Hz, 1H; C=CH2), 6.20 (dd, J = 10.7, 16.8 Hz, 1H; 
C=CH), 6.04 (d, J = 10.7 Hz, 1H; C=CH2), 3.19 (s, 3H; N-CH3). 
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13C NMR: (125 MHz, Chloroform-d3): δ 178.0, 165.1, 141.5, 141.4, 133.8, 133.2, 129.1 
(2C), 128.9, 128.8 (2C), 127.6, 126.8 (2C), 122.9 (2C), 38.3.  
HRMS (ESI, m/z): calculated for C17H18N3O3S2 [M + H]+ 376.0784; found 376.0778 
(1.6 ppm). 
S
N
O O
N
H
N
H
O S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
Figure 1.45 1H and 13C NMR spectra of compound 1.70 [500 MHz for 1H, and 100 MHz 
for 13C, Chloroform-d3]. 
 
 
 
 
1.4.7 General Procedure for the synthesis of thiourea compounds (1.2, 1.10-1.16, 
1.75-1.87). 
The carboxylic acid 1.41-1.39, 1.70-1.72 (1 eq.) was refluxed with thionyl chloride 
(120 eq.) and the mixture heated under reflux for 3 hours. The solution was cooled to 
room temperature and concentrated under reduced pressure. The residue was further dried 
via high vacuum and used in the proceeding reaction without further purification. KSCN 
(1-2 eq.) was added to the solution of crude acyl chloride in anhydrous acetonitrile (0.5 
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M) and the reaction was allowed to stir for 4 hours at room temperature. The solid KCl 
was removed through filtration and the aniline 1.57-1.68 (1 eq.), dissolved in acetonitrile 
(0.1 M), was added drop wise to the filtrate and the mixture stirred for 24 hours.21 The 
product either precipitated and needed no further purification, recrystallized using the 
appropriate mixture of solvents or purified via flash column chromatography or 
preparative HPLC.  
(E)-3-(2-Methoxyphenyl)-N-((4-(N-methyl-N-
phenylsulfamoyl)phenyl)carbamothioyl)acrylamide (1.2). The product precipitated as 
a pure yellow solid. Yield (25 mg, 46%).  
1H NMR (500 MHz, Acetone-d6): δ 8.05 (d, J = 15.5 Hz, 1 H, Ar-CH=), 7.95 (d, J = 8.6, 
2H, Ar-H), 7.56 (d, J = 8.6, 2H, Ar-H), 7.49 (dd, J = 1.7, 8.0 Hz, 1H, Ar-H), 7.42 (dd, J = 
1.7, 8.0 Hz, 1H, Ar-H ), 7.30 (m, 3H, Ar-H), 7.12 (s, 1 H, Ar-H), 7.10 (d, J = 7.5 Hz, 1 H, 
Ar-H), 7.00 (t, J = 7.5 Hz, 1 H, Ar-H), 6.96 (d, J = 8.6 Hz, 1 H, Ar-H), 6.66 (d, J = 15.5 
Hz, 1 H, C=CHCO), 3.19 (s, 3H; N-CH3), 3.94 (s, 3H; O-CH3).  
13C NMR (125 MHz, DMSO-d6): δ 179.4, 167.4, 158.9, 142.6, 141.6, 140.8, 133.3, 
133.1, 129.8, 129.5 (2C), 128.8 (2C), 127.8, 126.8 (2C), 123.9 (2C), 122.9, 121.4, 120.5, 
112.5, 56.2, 38.5.  
HRMS (ESI, m/z): Calculated for C24H24N3O4S2 [M + H]+ 482.1203; found 482.1184 
(3.9 ppm). 
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Figure 1.46 1H and 13C NMR spectra of compound 1.2 [500 MHz for 1H, Acetone-d6 and 
100 MHz for 13C, DMSO-d6]. 
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N-((4-(N-methyl-N-phenylsulfamoyl)phenyl)carbamothioyl)quinoline-3-
carboxamide (1.10). The product precipitated as a pure yellow solid. Yield (59 mg, 
65%).  
1H NMR (500 MHz, Acetone-d6): δ 9.40 (d, J = 2.3 Hz, 1H; Ar-H), 9.23 (s, 1H; Ar-H), 
8.26 (d, J = 8.6Hz, 1H; Ar-H), 8.22 (d, J = 8.0 Hz, 1H; Ar-H), 8.10 (dd, J = 6.3, 8.6 Hz, 
2H; Ar-H), 8.01 (d, J = 7.7 Hz, 1H; Ar-H), 7.80 (d, J = 7.5 Hz, 1H; Ar-H), 7.59 (d, J = 
8.9 Hz, 2H; Ar-H), 7.35-7.27 (m, 3H; Ar-H), 7.15 (dd, J = 1.7, 8.3 Hz, 2H; Ar-H), 3.22 
(s, 3H; N-CH3). 
13C NMR (100 MHz, DMSO-d6): δ 179.6, 167.4, 149.6, 149.5, 142.7, 141.6, 138.6, 
133.5, 132.8, 130.2, 129.5 (2C), 129.3, 128.8 (2c), 128.3, 127.8, 126.8 (2C), 126.5, 
125.6, 124.3 (2C), 38.5. 
HRMS (ESI, m/z): calculated for C24H21N4O3S2 [M + H]+ 477.1050; found 477.1030 
(4.1 ppm). 
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Figure 1.47 1H and 13C NMR spectra of compound 1.10 [500 MHz for 1H, Acetone-d6 
and 100 MHz for 13C, DMSO-d6]. 
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N-((4-(N-Methyl-N-phenylsulfamoyl)phenyl)carbamothioyl)quinoline-7-
carboxamide (1.11). Purification was done via recrystallization using a mixture of 
chloroform and hexane. Yield (8.0 mg, 11%).  
1H NMR (500 MHz, Acetone-d6): δ 9.02 (dd, J = 1.7, 4.0 Hz, 1H; Ar-H), 8.76 (s, 1H; 
Ar-H), 8.44 (dd, J = 1.2, 8.6 Hz, 1H; Ar-H), 8.14 (s, 2H), 8.11 (d, J = 8.6 Hz, 2H; Ar-H), 
7.66 (dd, J = 4.0, 8.6 Hz, 1H; Ar-H), 7.59 (d, J = 8.9 Hz, 2H; Ar-H), 7.35-7.27 (m, 3H; 
Ar-H), 7.15 (d, J = 8.0 Hz, 2H; Ar-H), 3.22 (s, 3H; N-CH3).  
13C NMR (125 MHz, DMSO-d6): δ. 179.0, 168.2, 152.1, 147.4, 142.4, 141.8, 135.9, 
133.7, 132.8, 130.9, 130.7, 129.0, 128.9 (2C), 128.6 (2C), 127.3, 126.6 (2C), 124.8, 
123.6, 123.2, 37.7. 
HRMS (ESI, m/z): Calculated for C24H21N4O3S2 [M + H]+ 477.1050; found 477.1030 
(4.1 ppm). 
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Figure 1.48 1H and 13C NMR spectra of compound 1.11 [500 MHz for 1H, Acetone-d6 
and 100 MHz for 13C, DMSO-d6]. 
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6-(2-Hydroxyethyl)-N-((4-(N-methyl-N-phenylsulfamoyl)phenyl)carbamothioyl)-2-
naphthamide (1.12). The residue was purified by preparative HPLC using a 
Phenomenex Gemini-NX column C18 (250 x 21.20 mm, 110 A, 5 μm spherical particle 
size). The column was perfused at a flow rate of 21.24 mL/min with a linear gradient 
from 60% (CH3CN-H2O) to 80% over 15 min. The compound eluted at 12.5 min. Yield 
(7.4 mg, 6%).  
1H NMR (500 MHz, Chloroform-d3): δ 9.26 (s, 1H; N-H), 8.40 (s, 1H; Ar-H), 7.98-7.92 
(m, 4H; Ar-H), 7.87 (dd, J = 1.4, 8.7 Hz, 1H; Ar-H), 7.57 (d, J = 8.7 Hz, 2H; Ar-H), 7.51 
(dd, J = 1.8, 8.2 Hz, 1H; Ar-H), 7.33-7.27 (m, 3H; Ar-H), 7.10 (dd, J = 1.8, 6.9 Hz, 2H; 
Ar-H), 3.99 (t, J = 6.4 Hz, 2H; O-CH2), 3.19 (s, 3H; N-CH3), 3.08 (t, J = 6.4 Hz, 2H; Ar-
CH2).  
13C NMR (100 MHz, Chloroform-d3): δ 178.1, 167.3, 141.7, 141.4, 140.5, 136.0, 133.8, 
131.3, 129.7, 129.4, 129.2, 129.1 (2C), 129.0, 128.9 (2C), 127.7, 127.6, 126.8 (2C), 
123.2, 123.0 (2C), 63.3, 39.5, 38.3.  
HRMS (ESI, m/z): Calculated for C27H26N3O4S2 [M + H]+ 520.1359; found 520.1339 
(3.9 ppm). 
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Figure 1.49 1H and 13C NMR spectra of compound 1.12 [500 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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(E)-N-((4-(N-(2-Hydroxyethyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.13). The product precipitated as a yellow solid. Yield 
(58%).  
1H NMR (500 MHz, Acetone-d6): δ 10.54 (s, 1H; N-H), 8.13 (d, J = 15.8 Hz, 1H; Ar-
CH=C), 8.08 (d, J = 8.6 Hz, 2H; Ar-H), 7.64-7.61 (m, 3H; Ar-H), 7.44 (d, J = 7.7 Hz, 
1H; Ar-H), 7.35-7.29 (m, 3H; Ar-H), 7.19 (d, J = 15.8 Hz, 1H; CH=CO), 7.14-7.10 (m, 
3H; Ar-H), 7.01 (t, J = 7.5 Hz, 1H; Ar-H), 3.94 (s, 3H; O-CH3), 3.83 (t, J = 5.7 Hz, 1H; 
O-H), 3.73 (t, J = 6.3 Hz, 2H, N-CH2), 3.54 (q, J = 6.0 Hz, 2H; O-CH2). 
13C NMR (125 MHz, Acetone-d6) δ 179.2, 167.3, 159.0, 142.3, 141.3, 139.9, 135.5, 
132.6, 129.5, 129.1 (2C), 129.0 (2C), 128.4 (2C), 127.9, 122.8 (2C), 120.9 (2C), 119.5, 
111.7 (2C), 59.6, 55.3, 53.2.  
HRMS (ESI, m/z): Calculated for C25H26N3O5S2 [M + H]+ 512.1308; found 512.1287 
(4.2 ppm). 
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Figure 1.50 1H and 13C NMR spectra of compound 1.13 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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(E)-3-(2-Methoxyphenyl)-N-((4-(N-methyl-N-(pyridin-4-
yl)sulfamoyl)phenyl)carbamothioyl)acrylamide (1.14). Purification was done via 
recrystallization using Methanol. Yield (12 mg, 15%).  
1H NMR (500 MHz, Chloroform-d3): δ 8.78 (s, 1H; N-H), 8.53 (dd, J = 1.7, 4.6 Hz, 2H; 
Ar-H), 8.06 (d, J = 15.8 Hz, 1H; Ar-CH=C), 7.97 (d, J = 8.9 Hz, 2H; Ar-H), 7.60 (d, J = 
8.6 Hz, 2H; Ar-H), 7.49 (dd, J = 1.7, 7.5 Hz, 1H; Ar-H), 7.43 (dd, J  = 1.7, 7.7 Hz, 1H; 
Ar-H), 7.18 (dd, J = 1.7, 4.7 Hz, 2H; Ar-H), 7.00 (t, J = 7.5 Hz, 1H; Ar-H), 6.96 (d, 8.6 
Hz, 1H; Ar-H), 6.65 (d, J = 15.8 Hz, 1H; C=CH-CO), 3.93 (s, 3H; N-CH3).  
13C NMR (125 MHz, Chloroform-d3): δ 178.5, 166.8, 159.2, 150.7 (2C), 148.8, 143.5, 
142.4, 133.2, 132.9, 130.9, 128.4 (2C), 123.1 (2C), 122.4, 121.0, 118.6, 118.3 (2C), 
111.4, 55.7, 36.7.  
HRMS (ESI, m/z): Calculated for C23H23N4O4S2 [M + H]+ 483.1155; found 483.1134 
(4.4 ppm). 
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Figure 1.51 1H and 13C NMR spectra of compound 1.14 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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(E)-N-((4-(N-((5-(Hydroxymethyl)furan-2-yl)methyl)-N-
phenylsulfamoyl)phenyl)carbamothioyl)-3-(2-methoxyphenyl)acrylamide (1.15). The 
product precipitated as a yellow solid. Yield (98 mg, 61%).  
1H NMR (500 MHz, Acetone-d6): δ 8.14 (d, J = 15.8 Hz, 1 H; Ar-CH=C), 8.08 (d, J = 
8.9 Hz, 2H; Ar-H), 7.66 (d, J = 8.6 Hz, 2H; Ar-H), 7.62 (dd, J = 1.7, 7.7 Hz, 2H; Ar-H), 
7.45 (dt, Jt  = 1.7, Jd  = 7.7 Hz, 1H; Ar-H), 7.28-7.25 (m, 3H; Ar-H), 7.19 (d, J = 15.5 Hz, 
1H; C=CHCO), 7.11 (d, J = 8.6 Hz, 1H; Ar-H), 7.07-7.05 (m, 2H; Ar-H), 7.01 (t, J = 7.5 
Hz, 1H; Ar-H), 6.05 (d, J = 3.2 Hz, 1H; Fu-H), 6.02 (d, J = 3.2 Hz, 1H; Fu-H), 4.84 (s, 
2H; O-CH2), 4.39 (s, 2H; N-CH2), 3.94 (s, 3H; O-CH3).  
13C NMR (125 MHz, Acetone-d6): δ 179.2, 167.3, 159.0, 155.9, 149.0, 142.3, 141.4 
(2C), 139.2, 135.7, 132.6, 129.5, 129.1 (2C), 128.9 (2C), 128.5 (2C), 128.0, 122.8 (2C), 
120.9, 119.5, 111.7, 110.3, 107.4, 56.4, 55.3, 47.8.  
HRMS (ESI, m/z): Calculated for C29H28N3O6S2 [M + H]+ 578.1414; found 578.1395 
(3.3 ppm). 
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Figure 1.52 1H and 13C NMR spectra of compound 1.15 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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(E)-3-(2-Methoxyphenyl)-N-((4-(N-
phenylsulfamoyl)phenyl)carbamothioyl)acrylamide (1.16). The product precipitated 
as a yellow solid. Yield (21 mg, 38%).  
1H NMR (500 MHz, Acetone-d6): δ 8.10 (d, J = 15.8 Hz, 1H; Ar-CH=C), 8.02 (d, J = 8.6 
Hz, 2H;Ar-H), 7.80 (d, J = 8.6 Hz, 2H; Ar-H), 7.59 (dd, J = 1.7, 7.7 Hz, 2H; Ar-H), 7.42 
(d, J = 8.1 Hz, 1H; Ar-H), 7.25-7.20 (m, 3H; Ar-H), 7.15 (d, J = 15.8 Hz, 1H; CH=CO), 
7.08 (d, J = 8.1 Hz, 1H; Ar-H), 7.07-7.03 (m, 2H; Ar-H), 7.01 (t, J = 7.5 Hz, 1H; Ar-H), 
3.91 (s, 3H; O-CH3). 
13C NMR (125 MHz, Acetone-d6): δ 179.2, 167.2, 159.0, 142.3, 141.3, 137.9, 136.7, 
132.6, 129.5, 129.2 (2C), 127.9 (2C), 124.6, 122.9 (2C), 122.8, 120.9 (2C), 119.5, 111.7 
(2C), 55.3.  
HRMS (ESI, m/z): Calculated for C23H22N3O4S2 [M + H]+ 468.1046; found 468.1028 
(3.9 ppm). 
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Figure 1.53 1H and 13C NMR spectra of compound 1.16 [500 MHz for 1H and 125 MHz 
for 13C, Acetone-d6]. 
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6-(Hydroxymethyl)-N-((4-(N-methyl-N-phenylsulfamoyl)phenyl)carbamothioyl)-2-
naphthamide (1.75). The product precipitated as a yellow solid. Yield (13.25 mg, 48%).  
1H NMR (500 MHz, Chloroform-d3): δ 9.26 (s, 1H; N-H), 8.40 (s, 1H; Ar-H), 7.98-7.92 
(m, 4H; Ar-H), 7.87 (dd, J = 1.4, 8.7 Hz, 1H; Ar-H), 7.57 (d, J = 8.7 Hz, 2H; Ar-H), 7.51 
(dd, J = 1.8, 8.2 Hz, 1H; Ar-H), 7.33-7.27 (m, 3H; Ar-H), 7.10 (dd, J = 1.8, 6.9 Hz, 2H; 
Ar-H), 3.99 (t, J = 6.4 Hz, 2H; O-CH2), 3.19 (s, 3H; N-CH3), 3.08 (t, J = 6.4 Hz, 2H; Ar-
CH2).  
13C NMR (100 MHz, Chloroform-d3): δ 178.1, 167.3, 141.7, 141.4, 140.5, 136.0, 133.8, 
131.3, 129.7, 129.4, 129.2, 129.1 (2C), 129.0, 128.9 (2C), 127.7, 127.6, 126.8 (2C), 
123.2, 123.0 (2C), 63.3, 39.5, 38.3.  
HRMS (ESI, m/z): Calculated for C26H24N3O4S2 [M + H]+ 506.1203; found 506.1186 
(3.3 ppm). 
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Figure 1.54 1H and 13C NMR spectra of compound 1.75 [500 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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N-((4-(N-(2-Hydroxyethyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)quinoline-7-
carboxamide (1.76). The product precipitated as a yellow solid. Yield (55%).  
1H NMR (500 MHz, Chloroform-d3): δ 9.42 (s, 1H; N-H), 9.07 (dd, J = 1.7, 4.0 Hz, 1H; 
Ar-H), 8.68 (s, 1H; Ar-H), 8.27 (dd, J = 1.2, 8.6 Hz, 1H; Ar-H), 8.05-8.02 (m, 2H; Ar-H), 
8.00 (d, J = 9.2 Hz, 2H; Ar-H), 7.66 (d, J = 9.2 Hz, 2H; Ar-H), 7.59 (dd, J = 4.0, 8.0 Hz, 
1H; Ar-H), 7.37-7.32 (m, 3H; Ar-H), 7.11-7.09 (m, 2H; Ar-H), 3.75 (m, 2H; O-CH2), 
3.68 (m, 2H; N-CH2).  
13C NMR (125 MHz, Chloroform-d3): δ 177.9, 166.7, 152.4, 147.4, 141.7, 139.3, 136.1, 
135.4, 132.0, 131.2, 120.0, 129.6, 129.5 (2C), 129.0 (2C), 128.7 (2C), 128.6, 124.1, 
123.8, 123.2 (2C), 60.5, 53.7.  
HRMS (ESI, m/z): Calculated for C25H23N4O4S2 [M + H]+ 507.1155; found 507.1145 
(2.0 ppm). 
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Figure 1.55 1H and 13C NMR spectra of compound 1.76 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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(E)-3-(2-Methoxyphenyl)-N-((4-(N-phenyl-N-(pyridin-4 
ylmethyl)sulfamoyl)phenyl)carbamothioyl)acrylamide (1.77). The product 
precipitated as a yellow solid. Yield (16.5 mg, 28%).  
1H NMR (500 MHz, Chloroform-d3): δ 8.69 (s, 1H, N-H), 8.53 (d, J = 6.0 Hz, 2H; Ar-
H), 8.07 (d, J = 15.5 Hz, 1H; Ar-CH=C), 8.00 (d, J = 8.6 Hz, 2H; Ar-H), 7.64 (d, J = 8.6 
Hz, 2H; Ar-H), 7.59 (dd, J = 1.7, 8.0 Hz, 2H; Ar-H), 7.43 (dt, Jt = 1.7, Jd = 8.0 Hz, 1H; 
Ar-H), 7.38 (d, J = 4.0 Hz, 2H; Ar-H), 7.28-7.26 (m, 3H; Ar-H), 7.04-7.00 (m, 3H; Ar-
H), 6.97 (d, J = 8.0 Hz, 1H; Ar-H), 6.66 (d, J = 15.5 Hz, 1H; CH=CO), 4.80 (s, 2H; N-
CH2), 3.95 (s, 3H; O-CH3). 
13C NMR (125 MHz, Chloroform-d3): δ 178.4, 166.7, 159.3, 149.5, 146.1, 143.6, 142.1, 
138.6, 134.9, 132.9, 130.9, 129.4 (2C), 128.7 (2C), 128.5, 123.4, 123.1 (2C), 122.4, 
121.0, 118.6, 11.5, 55.7, 53.9.  
HRMS (ESI, m/z): Calculated for C29H27N4O4S2 [M + H]+ 559.1396; found 559.1446. 
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Figure 1.56 1H and 13C NMR spectra of compound 1.77 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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N-((4-(N-((5-(Hydroxymethyl)furan-2-yl)methyl)-N-
phenylsulfamoyl)phenyl)carbamothioyl)quinoline-7-carboxamide (1.78). The product 
precipitated as yellow solid. Yield (45 mg, 34%).  
1H NMR (500 MHz, DMSO-d6): δ 12.04 (s, 1H; N-H), 9.02 (dd, J = 1.4, 4.1 Hz, 1H; Ar-
H), 8.64 (s, 1H; Ar-H), 8.46 (d, J = 8.2 Hz, 1H; Ar-H), 8.11 (d, J = 8.7 Hz, 1H; Ar-H), 
8.04 (dd, J = 1.7, 8.7 Hz, 1H; Ar-H), 7.99 (d, J = 8.7 Hz, 2H; Ar-H) 7.66 (dd, J = 4.1, 8.2 
Hz, 1H; Ar-H), 7.62 (d, J = 8.7 Hz, 2H; Ar-H), 7.27-7.25 (m, 3H; Ar-H), 7.00 (dd, J = 
2.3, 7.8 Hz, 2H; Ar-H), 6.04 (d, J = 3.2 Hz, 1H; Fur-H), 6.00 (d, J = 3.2 Hz, 1H; Fur-H), 
5.17 (t, J = 6.0 Hz, 1H; O-H), 4.78 (s, 2H; N-CH2), 4.24 (d, J = 6.0, 2H; O-CH2).  
13C NMR (125 MHz, Chloroform-d3):  δ 179.6, 168.2, 156.1, 152.1, 148.8, 142.7, 139.0, 
137.4, 135.4, 133.7, 130.8, 130.4, 129.4 (2C), 129.2, 129.1 (2C), 128.7 (2C), 128.7 (2C), 
128.5, 126.0, 124.3, 124.1, 110.8, 108.0, 56.1, 48.0. 
HRMS (ESI, m/z): Calculated for C29H25N4O5S2 [M + H]+ 573.1261; found 573.1243 
(3.1 ppm). 
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Figure 1.57 1H and 13C NMR spectra of compound 1.78 [500 MHz for 1H, DMSO-d6 and 
125 MHz for 13C, Chloroform-d3]. 
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(E)-N-((4-(N-(2-Hydroxybenzyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.79). The product precipitated as a yellow solid. Yield (39 
mg, 48%).  
1H NMR (400 MHz, Chloroform-d3): δ 8.62 (s, 1H, N-H), 8.07 (d, J = 15.6 Hz, 1H; Ar-
CH=C), 8.03 (d, J = 8.7 Hz, 2H; Ar-H), 7.73 (d, J = 8.7 Hz, 2H; Ar-H), 7.50 (d, J =  8.0 
Hz, 1H; Ar-H), 7.43 (t, J = 8.0 Hz, 1H; Ar-H), 7.27 (d, J = 2.3 Hz, 2H; Ar-H), 7.17-7.12 
(m, 1H; Ar-H), 7.02 (d, J = 7.8 Hz, 1H; Ar-H), 6.99-6.96 (m, 3H; Ar-H), 6.90 (d, J = 7.3 
Hz, 2H; Ar-H), 6.65 (d,  J = 15.6 Hz, 1H; CH=CO), 6.63 (d, J = 4.6 Hz, 2H; Ar-H), 4.71 
(s, 2H; N-CH2), 3.95 (s, 3H; O-CH3).  
13C NMR (100 MHz, Acetone-d6): δ 179.2, 167.3, 159.0, 155.0, 142.4, 141.4, 139.5, 
135.3, 132.6, 129.9, 129.5, 128.8 (2C), 128.7 (2C), 128.6, 128.5 (2C), 127.6, 122.9 (2C), 
122.9, 122.4, 119.5, 119.5, 115.2, 111.7, 55.3, 48.7.  
HRMS (ESI, m/z): Calculated for C30H28N3O5S2 [M + H]+ 574.1465; found 574.1449 
(2.8 ppm). 
S
N
O O
N
H
N
H
O S
HO
O
 
 
 
 
119 
 
Figure 1.58 1H and 13C NMR spectra of compound 1.79 [400 MHz for 1H, Chloroform-d3 
and 100 MHz for 13C, Acetone-d6]. 
 
 
 
  
120 
 
(E)-N-((4-(N-(3-Hydroxybenzyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.80). The product precipitated as a yellow solid. Yield (32 
mg, 44%).  
1H NMR (400 MHz, Chloroform-d3): δ 8.62 (s, 1H, N-H), 8.06 (d, J = 15.6 Hz, 1H; Ar-
CH=C), 7.97 (d, J = 8.7 Hz, 2H; Ar-H), 7.67 (d, J = 8.7 Hz, 2H; Ar-H), 7.50 (dd, J =  1.8, 
8.0 Hz, 1H; Ar-H), 7.43 (t, J = 8.0 Hz, 1H; Ar-H), 7.22 (dd, J = 1.8, 5.0 Hz, 2H; Ar-H), 
7.07 (t, J = 7.8 Hz, 1H; Ar-H), 7.03-6.96 (m, 4H; Ar-H), 6.75-6.72 (m, 2H; Ar-H), 6.67-
6.65 (m, 1H; Ar-H), 6.64 (d, J = 15.6 Hz, 1H; CH=CO), 4.70 (s, 1H; O-H),  4.68 (s, 2H; 
N-CH2), 3.94 (s, 3H; O-CH3). 
13C NMR (100 MHz, Acetone-d6): δ 179.2, 167.3, 159.0, 157.5, 142.4, 141.4, 139.3, 
138.2, 135.4, 132.6, 129.5, 129.4, 128.9 (2C), 128.8 (2C), 128.4 (2C), 127.7, 122.9 (2C), 
122.8, 120.9, 119.5, 119.4, 115.2, 114.5, 111.7, 55.3, 54.1.  
HRMS (ESI, m/z): Calculated for C30H28N3O5S2 [M + H]+ 574.1465; found 574.1438 
(4.7 ppm). 
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Figure 1.59 1H and 13C NMR spectra of compound 1.80 [400 MHz for 1H, Chloroform-d3 
and 100 MHz for 13C, Acetone-d6]. 
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(E)-N-((4-(N-(4-Hydroxybenzyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.81). The product precipitated as a yellow solid. Yield 
(104 mg, 54%).  
1H NMR (400 MHz, DMSO-d6): δ 11.76 (s, 1H; N-H), 9.31 (s, 1H; N-H), 7.99 (d, J = 
8.70 Hz, 2H; Ar-H), 7.94 (d, J = 16.0 Hz, 1H; Ar-CH=C), 7.63 (d, J = 8.7 Hz, 2H; Ar-H), 
7.54 (dd, J = 1.4, 7.8 Hz, 1H; Ar-H), 7.44 (dd, J = 7.3, 7.8 Hz, 1Hz; Ar-H), 7.23-7.09 (m, 
6H; Ar-H), 7.03 (d, J = 7.3 Hz, 1H; Ar-H), 6.99-6.95 (m, 5H; Ar-H), 6.56 (d, J = 8.2 Hz, 
2H; Ar-H), 4.64 (s, 2H; N-CH2), 3.87 (s, 3H; O-CH3).  
13C NMR (125 MHz, CDCl3): δ 178.1, 167.3, 142.3, 141.6, 141.4, 135.9, 133.7, 131.8, 
129.8, 129.5, 129.1 (2C), 129.0, 128.8 (2C), 128.2, 127.6, 126.8 (2C), 125.1, 123.3, 122.9 
(2C), 65.0, 38.3. 
HRMS (ESI, m/z): Calculated for C30H28N3O5S2 [M + H]+ 574.1465; found 574.1452 
(2.2 ppm). 
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Figure 1.60 1H and 13C NMR spectra of compound 1.81 [400 MHz for 1H, Chloroform-d3 
and 100 MHz for 13C, Acetone-d6]. 
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 (E)-N-((4-(N-(2-Hydroxyethyl)sulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.83).  
1H NMR (500 MHz, DMSO-d6): δ 12.95 (s, 1H; N-H), 11.70 (s, 1H; N-H), 7.95-7.92 (m, 
3H; Ar-H), 7.79 (d, J = 9.2 Hz, 2H; Ar-H), 7.59 (t, J = 6.1 Hz, 1H; Ar-H), 7.54 (dd, J = 
1.5, 7.6 Hz, 1H; Ar-H), 7.43 (dt, Jd = 1.5 , Jt = 7.6 Hz, 1H; Ar-H), 7.13 (d, J = 16.1 Hz, 
1H; Ar-CH=C), 7.10 (d, J = 7.6 Hz, 1H; Ar-H), 7.02 (t, J = 7.6 Hz, 1H; Ar-H), 4.66 (t, J 
= 6.1 Hz, 1H; O-H), 3.87 (s, 3H; O-CH3), 3.35 (q, J = 6.1 Hz, 2H; O-CH2), 2.78 (q, J = 
6.1 Hz, 2H; N-CH2).  
13C NMR (125 MHz, DMSO-d6): δ 179.7, 167.4, 158.9, 141.7, 140.7, 138.0, 133.0, 
129.8, 127.7 (2C), 124.6 (2C), 122.8, 121.5, 120.6, 112.4, 60.5, 56.2, 45.6. 
HRMS (ESI, m/z): Calculated for C19H22N3O5S2 [M + H]+ 436.0995; found 574.1452 
(1.7 ppm). 
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Figure 1.61 1H and 13C NMR spectra of compound 1.83 [500 MHz for 1H and 100 MHz 
for 13C, DMSO-d6]. 
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(E)-N-((4-(N-(2,3-Dihydroxypropyl)sulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.84). The product precipitated as a yellow solid. Yield (77 
mg, 59%).  
1H NMR (400 MHz, DMSO-d6): δ 12.95 (s, 1H; N-H), 11.73 (s, 1H; N-H), 7.95-7.91 (m, 
3H; Ar-CH=C and Ar-H), 7.78 (d, J = 8.7 Hz, 2H; Ar-H), 7.58-7.52 (m, 2H; Ar-H), 7.43 
(t, J = 7.3 Hz, 2H; Ar-H), 7.13 (d, J = 15.6 Hz, 1H; C=CH), 7.10 (d, J = 8.7 Hz, 1H; Ar-
H), 7.01 (t, J = 7.3 Hz, 1H; Ar-H), 4.77 (d, J = 5.0 Hz, 1H; O-H), 4.53 (t, J = 6.0 Hz, 1H; 
O-H), 3.86 (s, 3H; O-CH3), 3.43 (dq, Jd = 6.9, Jq = 5.5 Hz, 1H; O-CH), 3.23 (m, 2H; O-
CH2-), 2.85 (m, 1H; N-CH2), 2.57 (m, 1H; N-CH2).  
13C NMR (125 MHz, DMSO-d3): δ 179.6, 167.4, 158.9, 141.7, 140.8, 138.0, 133.1, 
129.9, 127.8 (2C), 124.5 (2C), 122.8, 121.4, 120.5, 112.5, 70.9, 64.0, 56.2, 46.6. 
HRMS (ESI, m/z): Calculated for C20H24N3O6S2 [M + H]+ 466.1101; found 466.1088 
(2.8 ppm). 
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Figure 1.62 1H and 13C NMR spectra of compound 1.84 [400 MHz for 1H and 125 MHz 
for 13C, DMSO-d6]. 
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(E)-N-((4-(N-(3,4-Dimethylisoxazol-5-yl)sulfamoyl)phenyl)carbamothioyl)-3-(2-
methoxyphenyl)acrylamide (1.85). Yellow precipitate. Yield (63%).  
1H NMR (400 MHz, Chloroform-d3): δ 8.69 (s, 1H; N-H), 8.05 (d, J = 15.6 Hz, 1H; Ar-
CH=C), 8.02 (d, J = 8.7 Hz, 2H; Ar-H), 7.83 (d, J = 8.7 Hz, 2H; Ar-H), 7.49 (d, J = 7.6 
Hz, 1H; Ar-H), 7.42 (dt, Jd = 1.4, Jt = 8.0 Hz, 1H; Ar-H), 7.00 (t, J = 7.3 Hz, 1H; Ar-H), 
6.96 (d, J = 8.4 Hz, 1H; Ar-H), 6.65 (d, J = 15.6 Hz, 1H; C=CHCO), 6.63 (bs, 1H; SO2N-
H), 3.93 (s, 3H; O-CH3), 2.19 (s, 3H; Ar-CH3), 1.92 (s, 3H; Ar-CH3).  
13C NMR (125 MHz, Chloroform-d3): δ 179.4, 167.2, 161.6, 159.0, 155.4, 142.8, 141.4, 
137.0, 132.6, 129.5, 127.9, 123.3, 123.2, 122.8, 120.9, 119.5, 11.7, 106.5, 55.3, 9.9, 5.7. 
HRMS (ESI, m/z): Calculated for C22H23N4O5S2 [M + H]+ 487.1104; found 487.1088 
(3.4 ppm). 
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Figure 1.63 1H and 13C NMR spectra of compound 1.85 [400 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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N-((4-(N-phenyl-N-(Pyridin-4-ylmethyl)sulfamoyl)phenyl)carbamothioyl)quinoline-
7-carboxamide (1.86). The product precipitated as a yellow solid. Yield (80 mg, 63%).  
1H NMR (500 MHz, DMSO-d6): δ 12.74 (s, 1H; N-H), 12.02 (s, 1H; N-H), 9.02 (dd, 1.5, 
4.6 Hz, 1H; Ar-H), 8.65 (s, 1H; Ar-H), 8.46 (d, J = 8.4 Hz, 1H; Ar-H), 8.43 (d, J = 6.1 
Hz, 2H; Ar-H), 8.12 (d, J = 8.4 Hz, 1H; Ar-H), 8.05 (d, J = 8.4 Hz, 3H; Ar-H), 7.69-7.65 
(m, 3H; Ar-H), 7.29 (d, J = 5.4 Hz, 2H; Ar-H), 7.26 (d, J = 7.6 Hz, 2H; Ar-H), 7.23-7.20 
(m, 1H; Ar-H), 7.11 (d, J = 6.9 Hz, 2H; Ar-H), 4.87 (s, 2H; N-CH2)  
13C NMR (125 MHz, DMSO-d6): δ 179.6, 168.3, 152.5 (2C), 150.1 (2C), 147.1, 146.2, 
142.9, 139.1, 136.5, 134.7, 133.4, 131.1, 130.8, 129.6 (2C), 129.1, 128.8 (2C), 128.7 
(2C), 128.5, 125.7, 124.4, 124.1, 123.4 (2C), 53.2. 
HRMS (ESI, m/z): Calculated for C29H24N5O3S2 [M + H]+ 554.1315; found 554.1298 
(3.1 ppm). 
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Figure 1.64 1H and 13C NMR spectra of compound 1.86 [500 MHz for 1H and 125 MHz 
for 13C, DMSO-d6]. 
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N-((4-(N-(4-Hydroxybenzyl)-N-phenylsulfamoyl)phenyl)carbamothioyl)quinoline-7-
carboxamide (1.87). The product precipitated as a yellow solid. Yield (42.5 mg, 29%).  
1H NMR (400 MHz, DMSO-d6): δ 12.73 (s, 1H; N-H), 12.04 (s, 1H; N-H), 9.13 (bs, 1H; 
O-H), 9.03 (dd, J = 1.8, 4.1 Hz, 1H; Ar-H), 8.65 (s, 1H; Ar-H), 8.48 (d, J = 7.8 Hz, 1H; 
Ar-H), 8.12 (d, J = 8.2 Hz, 1H; Ar-H), 8.07-8.01 (m, 3H; Ar-H), 7.69-7.64 (m, 3H; Ar-
H), 7.24-7.16 (m, 3H; Ar-H), 6.99-6.96 (m, 4H; Ar-H), 6.56 (d, J = 8.2 Hz, 2H; Ar-H), 
4.65 (s, 2H, N-CH2).  
13C NMR (125 MHz, Chloroform-d3): δ 179.5, 157.4, 152.2, 147.1, 142.6, 139.1, 136.7, 
135.5, 133.4, 131.1, 130.8, 130.1 (2C), 129.3 (2C), 129.1 (2C), 128.6 (2C), 128.2, 126.6, 
125.7, 124.4 (2C), 124.0, 115.6, 53.8. 
HRMS (ESI, m/z): Calculated for C30H25N4O4S2 [M + H]+ 569.1312; found 569.1295 
(2.9 ppm). 
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Figure 1.65 1H and 13C NMR spectra of compound 1.87 [400 MHz for 1H, DMSO-d6, and 
125 MHz for 13C, Chloroform-d3]. 
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CHAPTER II 
 
ISOLATION, SEMISYNTHESIS, COVALENT DOCKING AND TRANSFORMING 
GROWTH FACTOR BETA-ACTIVATED KINASE 1 (TAK1)-INHIBITORY 
ACTIVITIES OF (5Z)-7-OXOZEAENOL ANALOGUES 
 
2.1 Introduction 
Transforming growth factor-β-activated kinase 1 (TAK-1) is a member of the 
serine/threonine mitogen-activated protein kinase kinase kinase (MAP3K) family.1 A 
wide range of extracellular stimuli, such as proinflammatory interleukins, activate the 
intracellular TAK-1 via membrane-bound receptors.2 Turning on the upstream key 
signaling enzyme results in subsequent phosphorylation of specific MAP2Ks and 
MAPKs which, in turn, activates a number of transcription factors including AP-1 and 
NF-κB.3 These DNA-binding proteins are known to regulate inflammatory responses and 
apoptosis. Inhibition of upstream kinases such as MAP3Ks has an advantage over 
inhibiting downstream signaling molecules, mostly due to the former being more stimuli-
specific.4 Indeed, it has been shown that inhibiting TAK-1/NF-κB signaling pathway, 
using either TAK-1 inhibitors or via silencing its expression, promotes apoptosis in colon 
cancer,5 suppresses renal cell carcinoma survival,6 inhibits proliferation of LPS-induced 
human hepatocellular carcinoma,7 and reverses chemo resistance of pancreatic cancer.8 
In 1978, Ellestad et al. isolated (5Z)-7-oxozeaenol (2.1) (Figure 2.1), a β-resorcylic 
acid lactone, from an unidentified fungus9 and in 2003 it was found that 2.1 was a potent
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inhibitor of TAK-1 with an IC50 of 8.1 nM.10 Similar to almost all other kinase 
inhibitors,11 (5Z)-7-oxozeaenol is a competitive ATP ligand that binds covalently to its 
target.10 This irreversible interaction was determined when the covalently-bound ligand 
was cocrystalized with TAK-1.12 The surging interest in discovering and developing 
small molecule covalent inhibitors stems from the fact that these ligands would have 
increased selectivity to their targets and therefore less intense side effects, resulting from 
dose reduction of the candidate drug to achieve therapeutic effects.13 Selectivity of 
covalent inhibitors between kinases is difficult to achieve because the target is the ATP-
binding pocket which is highly conserved.14 However, the selectivity profile improves 
when moving from biochemical to cell-based kinase screening.  There was a promising 
degree of selectivity for (5Z)-7-oxozeaenol since a 1 µM concentration exhibited at least 
50% inhibition for only 12 of the 85 kinases tested by Wu et al, while, in cell lines, the 
TAK-1 signaling pathway was demonstrated to be most sensitive to the macrolide 
inhibitor.12 Due to the selective and potent activity with this medicinally important 
receptor, it was decided that (5Z)-oxozeaenol was worth further analysis. 
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Figure 2.1 Structures of isolated resorcylic acid lactones from different fungal strains. 
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activities.  Semisynthetic analogues were prepared using (5Z)-7-oxozeaenol as the 
starting material.  Bioassay and covalent docking of the synthesized and isolated 
analogues were carried out to correlate, at a molecular level, structural changes with 
OH
O
O
O O
HO
OH
OH
O
O
O
O
OH
OH
(5Z)-7-Oxozeaenol (1) (5E)-7-Oxozeaenol (2)
OH
O
O
O
OH
OH
Zeaenol (3)
OH
OH
O
O
O O
HO
OH
LL-Z1640-1 (7)
OH
O
O
O
O
OH
OH
Aigialomycin A (6)
O
OH
O
O
O O
HO
OH
Hypothemycin (4)
O
OH
O
O
O O
HO
OH
O
Dihydrohypothemycin (5)
O
OO
HO
O
Greensporone C (8)
A
143 
 
variations in inhibitory activity. These data are presented to establish initial structure-
activity relationships for (5Z)-7-oxozeaenol’s TAK-1 activity. 
2.2 Results and Discussion 
2.2.1 Isolation of (5Z)-7-oxozeaenol (2.1) and related secondary metabolites 
The lead compound in this study, (5Z)-7-oxozeaenol (2.1), and six related analogues 
(Figure 2.1) were isolated from solid-phase cultures of MSX 63935 as previously 
described in detail.15 The decision of choosing 2.1 as the lead for further diversification 
was primarily due to the greater potency in inhibiting NF-κB (11 nM).15  Fortuitously, the 
relative amount of cis-enone 2.1 was much higher in the extract compared to all other 
metabolites.15 
2.2.2 Synthesis of (5Z)-7-oxozeaenol analogues 
For treatment of inflammation and cancer, (5Z)-7-oxozeaenol (2.1) is a potent 
inhibitor of the kinase target TAK-1; however, its progress in the clinic has been stalled 
largely due to instability in plasma.17 Thus, there is an opportunity to diversify this 
scaffold to generate analogues with improved activity and/or improved pharmaceutical 
properties. It is our understanding, based on some of the products obtained, that cis-enone 
2.1 is sensitive to both acidic and basic conditions. These conditions, in any reaction, 
resulted in isomerization, elimination, or intramolecular cyclization products.  
2.1.1.1 Methylation of ring A-phenolic hydroxyl 
The free phenol was the first appealing position to diversify. The main reason for 
methylating the phenol was to verify the prior hypothesis that the phenol hydrogen bonds 
to the carbonyl of nearby residue Pro160.12 The use of diazomethane18 or iodomethane 
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with sodium hydride19 did not result in the methylation of the alcohol, at carbon 17, as 
indicated by 1H NMR spectroscopy. Instead, the macrolactone 2.1 either decomposed or 
was unreactive under those conditions.  The hydroxyl hydrogen is strongly chelated to the 
nearby ester carbonyl oxygen, as can be inferred from the strong sharp peak at 12 ppm in 
1H NMR spectrum of 2.1. The use of potassium carbonate20 or tetrabutylammonium 
hydroxide21 in DMF produced a reaction, but only elimination instead of substitution 
(Scheme 2.1).  Dienoates 2.9 and 2.10 suggest that the strong bases deprotonated one of 
the hydrogens on carbon 3 and led to elimination of the ester attached to carbon 3 
(Scheme 2.1). Under these more forcing conditions, the phenolic hydroxyl group was 
found to react with excess iodomethane.  The stereochemical configurations of 
compounds 2.9 and 2.10 were assigned as (3E,5Z) based on the coupling constants 
between the protons at C3/C4 and C5/C6 (i.e. 13.8 Hz and 11.5 Hz, respectively). 
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Scheme 2.1 Synthesis of compounds 1.9-1.16. Reagents and conditions a) K2CO3, DMF, 
CH3I or Bu4NOH, DMF, CH3I, r.t; b) 6 eq. Selectfluor®, CH3CN; c) NBS, CHCl3; d) 
Dimethoxy propane, 0.2 eq.  p-TSA; e) Dimethoxy propane, 2 mg p-TSA. 
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2.1.1.2 Fluorination of ring A 
There has been an increased interest in introducing fluorine atoms into drug 
candidates for the enhanced pharmaokinetics and pharmacodynamics that this atom 
provides. More than 25% of marketed drugs have at least fluorine atom in their 
structures.22 The small size and large electronegativity of this heteroatom often leads to 
an increase in drug potency and half-life due to decreased metabolism. In light of these 
advantages, fluorination was attempted. The reagent of choice for this reaction was the 
electrophilic Selectfluor® which usually has high levels of reactivity and selectivity.23 
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Fluorination using fluorine radicals would probably not be as selective due to competition 
from the double bond at carbons 11 and 12 of the macrocycle.  Surprisingly, the product 
obtained was a result of difluorination at carbon 14 (Scheme 2.1). A reasonable 
explanation for disubstitution at the more sterically accessible carbon is the strong 
activation of the nucleophilic aromatic ring by the two electron-donating oxygens at 
carbons 15 and 17.  Attempts to synthesize the monofluorinated compound led only to 
reduced yields of the difluorinated product. 
2.1.1.3 Bromination of ring A 
In a separate attempt to introduce fluorine into the molecule, trifluoromethylation 
was carried out. Unexpectedly, the major product obtained when using sodium 
trifluoromethane sulfinate, copper (II) trifluoromethane sulfonate and hydrogen 
peroxide24 resulted in the formation of bromide 2.12 (Scheme 2.1). It is surmised that the 
trace impurities of a bromine-containing contaminant, as suggested by mass analysis of 
sodium trifluoromethane sulfinate, was the source of reactive bromine (Figure 2.2). 
Interestingly, when arene 2.1 was treated with NBS, bromination at the other position 
(i.e. C14), and at both positions occurred (Scheme 2.1).25 
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Figure 2.2 (A) (+)-ESI TIC of Sodium trifluoromethanesulfinate. (B) UPLC-PDA 
chromatogram. (C) m/z spectrum. 
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2.1.1.4 Synthesis of (5Z)-7-oxozeaenol acetonide 
To investigate the importance of the free hydroxyl groups at carbons 8 and 9 for 
activity, acetonide formation was targeted. The use of acetone with dimethyl sulfoxide26 
was not successful to prepare the target product, however, dimethoxypropane with 
catalytic amounts of p-toluenesulfonic acid was successful if only few crystals9 of the 
acid were used. Larger amounts than only a few crystals27 activated the carbonyl at 
carbon 7 and facilitated intramolecular conjugate addition of the oxygen at carbon 9 to 
give pyranone 2.15 (Scheme 2.1). 
2.1.1.5 Attempts to synthesize open-ring 2.17, 5, 6-epoxy 2.18, thionoester 2.19, 
desmethyl 2.20 and lactam 2.21 derivatives of (5Z)-7-oxozeaenol. 
Saponification of 2.1 (Scheme 2.2) to acquire the acyclic derivative 2.17 was 
attempted using sodium hydroxide in dimethyl sulfoxide or water28 or LiOH in a mixture 
of tetrahydrofuran and water.29 The strong basic conditions led only to degradation of 2.1 
as indicated by 1H NMR analysis of the crude reaction mixture. 
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Scheme 2.2 Attempted synthesis of 5(Z)-7-oxozeanol derivatives 2.17-2.21. Reagents and 
conditions: a) NaOH, DMSO or H2O; b) LiOH, THF/H2O; c) t-BuOOH, t-BuOOK, THF; 
d) Lawesson reagent, Toluene, 120 °C; e) BBr3, CH2Cl2, -78 °C; f) i) RN3, catalyst ii) 
PPh3 iii. NHS, DCC. 
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Decreasing the alkylating potency of the michael acceptor in 2.1 will potentially 
increase its selectively to react with Cys174 sulfur in the enzyme-binding pocket due to 
proximity. For that reason, conversion of the 5, 6-enone in 2.1 to the corresponding 5, 6-
epoxy derivative 2.18 was attempted (Scheme 2.2). Yet, the use of the conventional 
nucleophilic peroxides, such as cumene hydroperoxide and hydrogen peroxide, in the 
presence of tert-butoxide30 did not result in any change as indicated by 1H NMR analysis. 
Thiation of the 5, 6-enone in 2.1, using Lawesson reagent in toluene,31 to give 2.19 
(Scheme 2.2) was attempted to investigate the biological effects of increasing the michael 
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acceptor reactivity upon substituting the carbonyl oxygen in 2.1 with the less 
electronegative sulfur.32 The product obtained is presumed, based on 1H NMR analysis of 
the purified product, to be a dimer of 2.1 and Lawesson reagent monomer.  Due to the 
instability of the isolated major product, which hindered complete data collection and 
definite structural identification, alongside its unexciting nature, it was decided that the 
product was unworthy of any further investigation. 
Demethylation of ring A methoxy group in 2.1, to give the desmethyl derivative 2.20 
(Scheme 2.2), will be crucial in investigating the effect on activity upon increasing 
hydrogen bonding likelihood at that position with the nearby Tyr106.  However, the 
reagent of choice; tribromoborane (BBr3) resulted only in isomerization of the (5Z)-enone 
to the corresponding (5E)-enone 2.2. 
The primary reason for the instability of (5Z)-7-oxozeaenol 2.1 in plasma is due to 
macro lactone ring opening via esterases.17 Thus, conversion to the lactam derivative 2.21 
was attempted. The seemingly most applicable method was via opening the 14-membered 
ring via azide intermediate 2.21 formation33 followed by Staudinger mild reduction to the 
amine and in situ intramolecular lactam formation 2.22 catalyzed by the use of N-
hydroxy succinmide NHS and dicyclohexylcarbodiimide DCC34 (Scheme 2.2). Sodium 
azide NaN3 or trimethylsilyl azide TMSN3 were used as the azide sources without or with 
variant catalysts to prepare the azide intermediate 2.21 (Table 2.2). Yet, the products 
obtained were due to either ester elimination (i.e. entry 1) or 5, 6-enone isomerization 
(i.e. entry 2). SnCl4, BF3.Et2O and Cu(dppe)(OAc2) catalysts led to decomposition of 2.1 
(i.e. entries 2, 7-8). 
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Table 2.1 Attempts to synthesize the azide intermediate 2.21. 
 
Entry Azide source Catalyst Result 
1 NaN3 ------ Elimination 
2 NaN3 Cu(dppe)(OAc2) Decomposition 
3 TMSN3 FeCl3 No Change 
4 TMSN3 CeCl3 Isomerization 
5 TMSN3 AlCl3 No Change 
6 TMSN3 TiCl4 No Change 
7 TMSN3 SnCl4 Decomposition 
8 TMSN3 BF3.O(C2H5)2 Decomposition 
 
 
2.2.3 Biological testing 
Few isolated RALs 2.2-2.8 (Figure 2.1) and the semi synthesized analogues 2.10-
2.16 were evaluated for their in vitro TAK-1 inhibitory activities (Table 2.2). Compound 
2.9 was not tested due to its short-term stability as indicated by the sub 90% purity, 
detected by UPLC, following prep HPLC purification. The Michael acceptor is, as 
expected, a crucial part for the inhibitory activity of this group of compounds; loss of this 
functionality, involved in the covalent bond formation, whether through reduction of the 
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double bond or reduction of the carbonyl, leads to loss of activity as seen with zeaenol 
(2.3), LL-Z164-1 (2.7), dihydrohypothemycin (2.5), and pyranone 2.15. Not only is the 
enone presence crucial to the pharmacophore structure, the position matters also since 
shifting the enone from carbons 5-7 to carbons 9-11, as in greensborone C (2.8B 
diminishes activity. Additionally, isomerization of the enone double bond from a Z to an 
E configuration significantly reduces activity. This effect can be seen by comparing two 
different pairs of isomers, namely; (5Z)-7-oxozeaenol (2.1) versus (5E)-7-oxozeaenol 
(2.2) and hypothemycin (2.4) versus aigialomycin A (2.6). 
 
Table 2.2 IC50’s, docking scores and 95% confidence intervals of isolated and semi 
synthesized RALs. 
 
Compound Docking Score IC50 (µM) 95% Confidence Intervals 
1 -12.9 0.011 0.009-0.015 
4 -12.0 0.033 0.024-0.045 
11 -12.9 0.077 0.047-0.125 
13 -10.2 0.36 0.271-0.746 
16 -10.8 0.38 0.220-0.655 
6 N/Ab 0.99 NA 
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Table 2.2 IC50’s, docking scores and 95% confidence intervals of isolated and semi 
synthesized RALs. 
2 -11.5 1.3 0.932-1.780 
12 -10.0 2.6 2.206-3.150 
7 N/Ab 2.6 2.206-3.150 
14 -6.8 8.9 2188-3914 
3 N/Ab 10 8.168-12.441 
5 N/Ab >30 NA 
8 -8.4 >30 NA 
10 -6.4 >30 NA 
15 N/Ab >30 NA 
a The compounds are arranged in a descending order in regards to their inhibitory 
concentrations. 
b Compounds were not docked due to lacking the Michael acceptor functionality 
 
 
By comparing (5Z)-7-oxozeaenol (2.1) and hypothemycin (2.4), it can be inferred 
that epoxidation of the double bond on carbons 11 and 12 does not change the inhibitory 
activity. As mentioned by Chen et al., the hydroxyl group located at carbon 9 binds to the 
enzyme via formation of a hydrogen bond with the backbone carbonyl of Pro160.12 As 
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expected, blocking this interaction, as seen in acetonide 2.16, reduced the activity by 
more than 30 folds. The inability of compound 2.10 to inhibit TAK-1 indicates that the 
macrocycle is important for activity, probably due to the rigidity it provides to correctly 
position the Michael acceptor close to the nucleophilic cysteine residue. The only semi 
synthesized analogue that was found to be statistically equipotent to 2.1 is the difluoro 
(5Z)-7-oxozeaenol (2.11). The relative potency of compound 2.11 indicates that the 
aromatic ring is not crucial for binding. This observation with TAK1 is unprecedented. 
The crystal structure of 2.1 bound to TAK-1 indicates insufficient space to 
accommodate substituting the proton on carbon 16 with bromine. Thus, as expected, the 
16-Bromo analogue 2.12 was significantly less active. The better activity of 2.13 relative 
to 2.12 indicates that the binding pocket is more tolerant in accommodating the large 
bromine atom when installed in position 14 yet 2.13 was still significantly  less active 
than the parent ligand 2.1 .The added clashes of having two bromine atoms at positions 
14 and 16, renders the dibromo analogue 2.14 the least active.   
2.2.4 Covalent docking 
2.2.4.1 Ligand preparation 
Prior to docking, ligands having the Michael acceptor moiety were examined using 
Spartan (Wavefunction, Inc.). The structures of those ligands were first subjected to 
conformational searches using semi empirical molecular mechanics. The resulting 
conformers, ranging from 100-600, were further optimized using Hartree-Fock 
implementing the 6–31G* and 6-311G basis sets. The theoretical global minimum energy 
conformation was chosen to be docked into the crystal structure.  
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2.2.4.2 Covalent docking 
The prepared ligands were docked using the Chen et al.12 reported crystal structure 
(PDB 4GS6). The crystal structure was first prepared using protein preparation wizard 
(Maestro) and the prepared ligands were docked using covalent docking implemented in 
(Maestro). 
To validate the accuracy of the calculations performed in regards to our work, (5Z)-
7-oxozeaenol 2.1 was the first ligand to be docked. The best docking orientation, as 
judged by the docking score, was further subjected to protein refinement using prime 
implemented in Maestro followed by covalent docking of the minimization outputs.  
RMSD of the docking output superimposed to the crystal structure was found to be 
0.0984 °A (Figure 2.3). The configuration of the β carbon for the best-scored docking 
output is R. The geometry shown in the crystal structure is that of a sp2 carbon. It is 
assumed that the geometry of carbons 5 and 6 in the crystal structure are incorrectly 
assigned since both of these carbons should be sp3 hybridized after addition of the 
cysteine.  It is therefore not clear which model, R or S truly fits better for the preferred 
ligand binding geometry, but the R diastereomer is more consistent with the data.     
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Figure 2.3 (A) Superimposed covalent docking output pose (Purple) with the 
cocrystalized (5Z)-7-oxozeaenol (cayan). Parts of the enzyme’s residues (D175, F176 and 
G177), in the binding pocket, were deleted for clarification. 
 
 
 
Similar to the parent ligand, semi synthesized and isolated RALs, bearing an enone, 
were also docked covalently in the same previously described manner (Table 2.1). The 
scores obtained appear to be in an acceptable alignment with the experimental data.  
Distinct gaps are observed between compounds having inhibitory concentrations in the 
nM range, low μM range, and  inactive compounds. Analogues having low nM inhibitory 
concentration had docking scores of -12 to -12.9 Kcal/mol. A range of -10 to -11.5 
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Kcal/mol was representative of analogues with 0.4-2.6 μM range of activities. As for 
inactive compounds, they had considerably lower docking scores as compared with the 
active compounds.  In general, scoring based on the implemented covalent docking-prime 
minimization-covalent docking method proves to be considerably accurate in 
distinguisihing between active and inactive analogues.  
2.3 Experimental 
Unless otherwise stated, all reactions were carried out under an atmosphere of dry 
nitrogen in dried glassware. Indicated reaction temperatures refer to those of the reaction 
bath, while room temperature (rt) is noted as 25 °C. All solvents and reagents were 
obtained from commercial sources and were used as received. Analytical thin layer 
chromatography (TLC) was performed on silica gel 60 F254 precoated plates (0.25 mm) 
from Merck. Visualization was accomplished by irradiation under a 254 nm UV lamp. 
Silicycle silica gel 230−400 (particle size 40−63 μm) mesh was used for all flash column 
chromatography. The crude extract and reaction products were purified by reverse phase 
chromatography, which was performed using a Varian purification system employing a 
Phenomenex Gemini-NX, (5 µm, C18, 110A, AX. 250 × 21.20 mm) or a Phenomenex 
Kinete, (2.6 µm C18 100 Å, 30 x 2.1 mm). The mobile phase was a mixture of 
acetonitrile or and H2O containing 0.1% formic acid. 1H NMR spectra were recorded on a 
Jeol ECA 500 MHz spectrometer or a Jeol ECS 400 MHz spectrometer in the solvent 
indicated. All 1H NMR experiments are reported in δ units, parts per million (ppm) 
downfield of TMS , and were measured relative to the signals for chloroform (7.26 ppm), 
methanol (3.31 ppm), acetone (2.05 ppm) and dimethyl sulfoxide (2.50 ppm). All 13C 
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NMR spectra were reported in ppm relative to the signals for chloroform (77 ppm), 
methanol (49 ppm), acetone (29.8 ppm) and dimethyl sulfoxide (39.5 ppm) with 1H 
decoupled observation. Data for 1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, 
sept = septet, m = multiplet), integration and coupling constant (Hz), whereas 13C NMR 
analyses were reported in terms of chemical shift. High resolution mass spectra (HRMS) 
were performed on a Thermo Fisher Scientific UPLC/LTQ Orbitrap XL system.   
2.3.1 Isolation of (5Z)-7-oxozeaenol 
The purification of (5Z)-7-oxozeaenol (2.1) from solid phase cultures of MSX 63935 
has been described.15 Briefly, 800 mg of the extract was dissolved in 2 mL of DMSO and 
purified via 10 separate injections by preparative HPLC using a gradient that initiated 
with 35:65 (CH3CN/H2O) and increased linearly to 45:55 over 40 min. Compound 2.1 
and LL-Z164-1 2.7 eluted together from 16 to 20 min. The isolated mixture of (5Z)-7-
oxozeaenol 2.1 and LL-Z164-1 2.7 was subjected to an additional round of preparative 
HPLC under the same conditions to yield 206 mg (26%) of pure (>95%, Figure 2.4) (5Z)-
7-oxozeaenol.  
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Figure 2.4 UPLC chromatograms of compounds 2.1, 2.10-2.16 (λ 254 nm), 
demonstrating >97% purity for compounds 2.1, 2.10, 2.12-2.16. All data were acquired 
via an Acquity UPLC system with a Phenomenex Kinetex C18 (1.3 µm; 50 × 2.1 mm) 
column and a CH3CN/H2O gradient that increased linearly from 20 to 100% CH3CN over 
1.2 min. 
 
    
             (2.1)               (2.10) 
 
 
          (2.11)      (2.12) 
 
 
          (2.13)       (2.14) 
 
 
          (2.15)       (2.16) 
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2.3.2 Synthesis of (5Z)-7-oxozeaenol analogues 2.9-2.16 
Methyl 2-((1E,4S,5S,7Z,9Z)-4,5-dihydroxy-6-oxoundeca-1,7,9-trien-1-yl)-6-hydroxy-
4-methoxybenzoate (2.9).20  
Potassium carbonate (38.1 mg, 0.28 mmol) was added to a solution of (5Z)-7-
oxozeaenol (2.1) (50 mg, 0.14 mmol) in DMF (2 mL) and stirred for an hour. 
Iodomethane (10 μL, 0.16 mmol) was then added and the mixture stirred for 4 hours. It 
was diluted with water (20 mL) and acidified with 1M HCl, until a pH of 2, followed by 
extraction with CHCl3 (20 mLx3). The combined organic layers were dried using 
anhydrous sodium sulfate and the solvent evaporated. The residue was purified by 
preparative HPLC using a Phenomenex Gemini-NX column C18 (250 x 21.20 mm, 110 
A, 5 μm spherical particle size). The column was perfused at a flow rate of 21.24 mL/min 
with 70% of (water, 0.1% FA) and 30% of CH3CN over 80 min. The compound eluted at 
~ 70 min. Yield (6.6 mg, 13%).  
1H NMR (500 MHz, Chloroform-d3): δ  11.56 (s, 1H; 17-OH), 7.43 (dd, J = 11.5, 13.8, 
1H; 4-H), 6.98 (d, J = 15.5 Hz, 1H; 12-H), 6.57 (dd, J = 11.2, 11.5 Hz, 1H; 5-H), 6.37 (d, 
J = 2.9 Hz, 1H; 16-H), 6.25 (dq, Jd = 13.8, Jq 6.9 Hz, 1H; 3-H), 6.41 (d, J = 2.9 Hz, 1H; 
14-H), 6.08 (d, J = 11.5 Hz, 1H; 6-H), 5.84 (dt, Jd = 15.5, Jt  = 7.5 Hz, 1H; 11-H), 4.37 (bs, 
1H; 8-H), 3.95 (ddd, J = 4.6, 8.0, 8.2 Hz, 1H; 9-H), 3.91 (s, 3H; 21-H), 3.80 (s, 3H; 20-
H), 2.33-2.40 (m, 2H; 10-H), 1.90 (d, J = 6.9, 3H; 19-H).  
13C NMR (125 MHz, Chloroform-d3): δ 198.9, 171.5, 164.9, 164.2, 146.7, 145.2, 142.8, 
135.2, 129.3, 127.5, 117.9, 108.5, 103.7, 100.0, 79.4, 72.2, 55.5, 52.3, 35.7, 19.0.   
161 
 
HRMS (ESI, m/z): Calculated for C20H25O7 [M + H]+ 377.1595; found 377.1589 (1.5 
ppm). 
O
OOH
O
O
OH
OH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
Figure 2.5 1H and 13C NMR spectra of compound 2.9 [500 MHz for 1H and 125 MHz for 
13C, Chloroform-d3]. 
 
 
 
 
Figure 2.6 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.9. 
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Methyl 2-((1E,4S,5S,7Z,9Z)-4,5-dihydroxy-6-oxoundeca-1,7,9-trien-1-yl)-4,6-
dimethoxybenzoate (2.10).20  Same as procedure described for synthesis of compound 
2.9. The compound eluted at ~ 46 min. UPLC was used to evaluate the purity using a 
gradient solvent system that initiated with 20:80 CH3CN−H2O to 100% CH3CN over 4.5 
min; it was > 97% pure (Figure 2.4). Yield (18.0 mg, 34%).  
1H NMR (500 MHz, Chloroform-d3): δ  7.43 (dd, J = 11.5, 14.9 Hz, 1H; 4-H), 6.57 (d, J 
= 11.5 Hz, 1H; 5-H), 6.54 (d, J = 2.3 Hz, 1H; 14-H), 6.40 (d, J = 15.8 Hz, 1H; 12-H), 
6.34 (d, J = 2.3 Hz, 1H; 16-H), 6.24 (dq, Jd = 14.9, Jq = 6.9 Hz, 1H; 3-H), 6.13 (dt, Jd = 
15.8, Jt =  7.5 Hz, 1H; 11-H), 6.04 (d, J = 11.5 Hz, 1H; 6-H), 4.35 (d, J = 4.0 Hz, 1H; 8-
H), 3.95 (m, 1H; 9-H), 3.87 (s, 3H; 21-H), 3.80 (s, 3H; 22-H), 3.78 (s, 3H; 20-H),  2.38 
(m, 1H; 10-H), 2.26 (ddd, J = 4.0, 7.4, 14.3 Hz, 1H; 10-H), 1.89 (d, J = 6.9 Hz, 3H; 19-
H).  
13C NMR (125 MHz, Chloroform-d3): δ 198.8, 168.7, 161.6, 158.2, 146.9, 145.2, 137.8, 
130.5, 129.4, 129.3, 117.9, 115.3, 101.8, 97.9, 79.4, 72.4, 56.1, 55.5, 52.5, 35.9, 19.1. 
HRMS (ESI, m/z): Calculated for C21H27O7 [M + H]+ 391.1751; found 391.1745 (1.6 
ppm).  
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Figure 2.7 1H and 13C NMR spectra of compound 2.10 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
 
 
 
 
Figure 2.8 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.10. 
 
O
O
O
OH
O
O
OH
 
165 
 
(3S,5Z,8S,9S,11E)-13,13-Difluoro-8,9-dihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H benzo[c][1]oxacyclotetradecine-1,7,16(8H,13H)-trione (2.11).23 
Selectfluor® (177 mg, 0.50 mmol) was added to a solution of (5Z)-7-oxozeaenol (2.1) (30 
mg, 0.083 mmol) in CH3CN (3 mL) and the mixture stirred for 3 hrs.  The solvent was 
evaporated and the residue was purified by preparative HPLC using a Phenomenex 
Gemini-NX column C18 (250 x 21.20 mm, 110 A, 5 μm spherical particle size). The 
column was perfused at a flow rate of 21.24 mL/min with 60% (water, 0.1% TFA), and 
40% of MeOH over 40 min. The compound eluted at ~ 30 min.  UPLC was used to 
evaluate the purity using a gradient solvent system that initiated with 20:80 CH3CN−H2O 
to 100% CH3CN over 4.5 min; it was > 97% pure based on the ELSD detector (Figure 
2.9). Yield (27 mg, 14%). 
 
Figure 2.9 UPLC chromatogram of compound 2.11 (ELDS), demonstrating >98% purity. 
All data were acquired via an Acquity UPLC system with a Phenomenex Kinetex C18 
(1.3 µm; 50 × 2.1 mm) column and a CH3CN/H2O gradient that increased linearly from 
20 to 100% CH3CN over 1.2 min. 
 
                                     (11) 
 
 
 
 
1H NR (500 MHz, Chloroform-d3): δ 6.63 (dt, Jd = 11.5, Jt =  4 Hz, 1H; 5H), 6.35 (m, 
1H; 11-H), 6.31 (d, J = 11.5 Hz, 1H; 6-H), 6.07 (d, J = 15.5 Hz, 1H; 12-H), 5.58 (t, J = 
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2.3 Hz, 1H; 16-H), 5.43 (dq, Jd = 10.3 Hz, Jd = 6.3 Hz, 1H; 3-H), 4.47 (bs, 1H; 8-H), 4.11 
(m, 1H; 9-H), 3.85 (s, 3H; 20-H), 3.80 (m, 1H; 3-H), 2.57 (ddd, J = 6.9,  8.0, 15.5 Hz, 
1H; 10-H), 2.46 (d, 16.0 Hz, 1H; 4-H), 2.37 (dd, J = 5.2, 15.5 Hz, 1H; 10-H), 1.41 (d, J = 
6.3 Hz, 3H; 19-H).  
13C NMR (125 MHz, Chloroform-d3): δ 198.3, 181.4, 164.2, 163.1 (t, J = 24 Hz, 1C; 15-
C), 150.4, 140.3, 138.3 (t, J = 25 Hz, 1C; 13-C), 130.3 (t, J = 6 Hz, 1H; 18-C), 123.1, 
122.7, 109.0 (t, J = 241.5 Hz, 1C; 14-C), 102.3 (t, J = 4 Hz, 1H; 16-C), 80.7, 73.8, 72.6, 
57.0, 38.1, 37.2, 21.4. 
 19F NMR (376 MHz, Chloroform-d3): δ -103.30 (d, J = 355.2 Hz, 1F), -104.31 (d, J = 
355.2 Hz, 1F) (Figure 2.8). 
HRMS (ESI, m/z): Calculated for C19H21F2O7 [M + H]+ 399.1250; found 399.1242 (2.0 
ppm). 
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Figure 2.10 1H and 13C NMR spectra of compound 2.11 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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Figure 2.11 19F NMR spectra of compound 2.11 [376 MHz, Chloroform-d3]. 
 
 
 
 
Figure 2.12 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.11. 
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(3S,5Z,8S,9S,11E)-15-Bromo-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione (2.12).25 N-
Bromosuccinimide (7.4 mg, 0.04 mmol) was added to a solution of (5Z)-7-oxozeaenol 
(2.1)  (15 mg, 0.04 mmol)  in CHCl3 (1 mL) and the mixture stirred for 4 hours and the 
solvent evaporated. The residue was purified by preparative HPLC using a Phenomenex 
Gemini-NX column C18 (250 x 21.20 mm, 110 A, 5 μm spherical particle size). The 
column was perfused at a flow rate of 21.24 mL/min with a linear gradient from 40% 
(CH3CN-H2O) to 50% over 15 min. The compound eluted at 18.5 min. UPLC was used 
to evaluate the purity using a gradient solvent system that initiated with 20:80 
CH3CN−H2O to 100% CH3CN over 4.5 min; it was >97% pure (Figure 2.4). Yield (1.76 
mg, 14%).  
1H NMR (500 MHz, Chloroform-d3): δ 12.79 (s, 1H; 17-OH), 6.88 (d, J = 15.3 Hz, 1H; 
12-H), 6.42 (s, 1H; 14-H), 6.34 (dd, J = 3, 11.5 Hz, 1H; 6-H), 6.22 (dt, Jd = 11.5, Jt  = 3 
Hz, 1H; 5-H), 6.03 (ddd, J = 4.6, 10.7, 15.3 Hz, 1H; 11-H), 5.26 (dq, Jd = 6.1, Jq = 8.5 
Hz, 1H; 3-H), 4.53 (dd, J = 2.3, 5.4 Hz, 1H; 8-H), 4.00 (bs, 1H; 9-H), 3.95 (s, 3H; 20-H), 
3.57 (ddd, J = 5.4, 10.7, 11.5 Hz, 1H; 4-H), 2.53 (dd, J = 2.3, 17.6 Hz, 1H; 4-H), 2.23-
2.11 (m, 2H; 10-H), 1.48 (d, J = 6.1 Hz, 3H; 19-H).  
13C NMR (100 MHz, Chloroform-d3): δ 199.0, 171.1, 161.4, 160.4, 147.6, 142.3, 132.9, 
131.1, 125.3, 104.8, 103.7, 99.1, 80.9, 74.6, 73.6, 56.5, 37.5, 37.1, 20.8.  
HRMS (ESI, m/z): Calculated for C19H2279BrO7 [M + H]+ 441.0543; found 441.0546 (0.6 
ppm), Calculated for C19H2281BrO7 [M + H]+ 443.0523; found 443.0521 (0.4 ppm).  
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Figure 2.13 1H and 13C NMR spectra of compound 2.12 [500 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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Figure 2.14 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.12. 
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(3S,5Z,8S,9S,11E)-13-Bromo-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione25 (2.13). Same as 
procedure described for synthesis of compound 2.12. The compound eluted at 14.5 min. 
UPLC was used to evaluate the purity using a gradient solvent system that initiated with 
20:80 CH3CN−H2O to 100% CH3CN over 4.5 min; it was >97% pure (Figure 2.4). Yield 
(6.36 mg, 52%).  
1H NMR (500 MHz, Chloroform-d3): δ 12.12 (s, 1H; 17-OH), 6.43 (s, 1H; 16-H), 6.39 
(dd, J = 2.0, 15.3 Hz, 1H; 12-H), 6.31 (dd, J = 2.9, 11.5 Hz, 1H; 6-H), 6.18 (ddd, J = 2.9, 
10.9, 11.5 Hz, 1H; 5-H), 5.72 (ddd, J = 3.2, 10.3, 16.0 Hz, 1H; 11-H), 5.40 (dq, Jd = 8.5, 
Jq = 6.1 Hz, 1H; 3-H), 4.55 (bs, 1H; 8-H), 3.95 (bs, 1H; 9-H), 3.89 (s, 3H; 20-H), 3.74 (d, 
J = 4.0 Hz, 1H; 8-OH), 3.35 (ddd, J = 5.4, 10.9 Hz, 1H; 4-H), 2.51 (dd, J = 2.3, 17.2 Hz, 
1H; 4-H), 2.33 (dd, J = 2.3, 16.6 Hz, 1H; 10-H), 2.10 (ddd, J = 2.9, 10.3, 16.6 Hz, 1H; 
10-H), 1.46 (d, J = 6.1 Hz, 3H; 19-H).  
13C NMR (125 MHz, Chloroform-d3): δ 199.4, 170.9, 164.4, 161.1, 146.6, 142.2, 133.9, 
129.6, 125.6, 105.8, 105.4, 99.5, 81.0, 73.8, 73.1, 56.7, 37.0, 36.8, 21.0.   
HRMS (ESI, m/z): Calculated for C19H2279BrO7 [M + H]+ 441.0543; found 441.0546 (0.6 
ppm), Calculated for C19H2281BrO7 [M + H]+ 443.0523; found 443.0522 (0.2 ppm).  
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Figure 2.13 1H and 13C NMR spectra of compound 2.13 [500 MHz for 1H and 125 MHz 
for 13C, Chloroform-d3]. 
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Figure 2.14 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.13. 
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 (3S,5Z,8S,9S,11E)-13,15-Dibromo-8,9,16-trihydroxy-14methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione (2.14).25  Same as 
procedure described for synthesis of compound 2.12. The compound eluted at 21 min. 
UPLC was used to evaluate the purity using a gradient solvent system that initiated with 
20:80 CH3CN−H2O to 100% CH3CN over 4.5 min; it was >97% pure (Figure 2.4). Yield 
(1.42 mg, 10%).  
1H NMR (500 MHz, Chloroform-d3): δ 12.46 (s, 1H; 17-OH), 6.37 (d, J = 16.0 Hz, 1H; 
12-H), 6.32 (dd, J = 2.9, 11.5 Hz, 1H; 6-H), 6.20 (ddd, J = 2.9, 10.9, 11.5 Hz, 1H; 5-H), 
5.72 (ddd, J = 3.4, 10.3, 16.0 Hz, 1H; 11-H), 5.47 (dq, Jd = 6.3, Jd  = 11.5 Hz, 1H; 3-H), 
4.55 (dd, J = 2.3, 5.2, 1H; 8-H), 4.55 (dd, J = 2.3, 5.2 Hz, 1H; 8-H), 3.95 (bs, 1H; 9-H), 
3.90 (s, 3H; 20-H), 3.72 (d, J = 5.2 Hz, 1H; 8-OH), 3.40 (ddd, J = 10.9, 11.2, 11.5 Hz, 
1H; 4-H), 2.53 (ddd, J = 2.3, 2.9, 17.5, Hz, 1H; 4-H), 2.33 (m, H; 10-H), 2.13 (ddd, J = 
2.3, 10.3, 16.6, Hz, 1H; 10-H), 1.39 (d, J = 6.3 Hz, 3H; 19-H).  
13C NMR (100 MHz, Chloroform-d3): δ 199.2, 170.5, 160.0, 159.6, 146.4, 141.3, 134.6, 
129.1, 125.1, 104.7, 103.6, 99.0, 80.9, 74.8, 73.0, 60.6, 37.0, 36.8, 21.   
HRMS (ESI, m/z): Calculated for C19H2179Br2O7 [M + H]+ 518.9648; found 518.9633 
(3.0 ppm), Calculated for C19H2179Br 81BrO7 [M + H]+ 520.9628; found 520.9613 (2.9 
ppm), Calculated for C19H2181Br2O7 [M + H]+ 522.9608; found 522.9593 (2.8 ppm). 
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Figure 2.15 1H and 13C NMR spectra of compound 2.14 [500 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
 
 
 
 
Figure 2.16 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.14. 
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(12S,13S,8S,E)-13,53-Dihydroxy-55-methoxy-8-methyl13,14,15,16-tetrahydro-12H-
7-oxa-1(2,6)-pyrana-5(1,2) benzenacyclononaphan-3-ene-14,6-dione (2.15).27 p-
Toluenesulfonic acid (7.9 mg, 0.041 mmol) were added to a solution of (5Z)-7-
oxozeaenol (2.1) (15.0 mg, 0.041 mmol) in CH2Cl2 (2 mL) and the mixture stirred 
overnight.  It was extracted with 10% NaHCO3 (2mL), the organic layer dried and the 
solvent evaporated.  The residue was purified by preparative HPLC using a Phenomenex 
Gemini-NX column C18 (250 x 21.20 mm, 110 A, 5 μm spherical particle size). The 
column was perfused at a flow rate of 21.24 mL/min with (water, 0.1% TFA), and a 
linear gradient from 40% to 50% of CH3CN over 30 min. The compound eluted at 28.5  
min. UPLC was used to evaluate the purity using a gradient solvent system that initiated 
with 20:80 CH3CN−H2O to 100% CH3CN over 4.5 min; it was >97% pure (Figure 2.4). 
Yield (5.2 mg, 35%). 
1H NMR (400 MHz, Chloroform-d3): δ 11.19 (s, 1H; 17-OH), 7.13 (d, J = 16.0 Hz, 1H; 
12-H), 6.36 (d, J = 2.8 Hz, 1H; 16-H), 6.33 (d, 2.8 Hz, 1H; 14-H), 5.83 (ddd, J = 6.4, 6.9, 
16.0 Hz, 1H; 11-H), 5.16 (dq, J = 3.2, 6.4 Hz, 1H; 3-H), 4.64 (m, 1H; 5-H), 4.11 (dd, J = 
4.1, 9.6 Hz, 1H; 8-H), 3.85 (ddd, J = 2.8, 8.2, 10.1 Hz, 1H; 9-H), 3.80 (s, 3H; 20-H), 3.55 
(d, J = 4.1 Hz, 1H; 8-OH), 2.89 (dd, J = 6.9, 15.1 Hz, 1H; 6-H), 2.72 (dd, J = 7.0, 14.5 
Hz, 1H; 10-H), 2.48 (dd, J = 3.7, 15.1 Hz, 1H; 6-OH), 2.41 (m, 1H; 10-H), 2.21 (ddd, J = 
4.1, 6.6, 8.2 Hz, 1H; 4-H), 1.56 (m, 1H; 4-H), 1.41 (d, J = 6.0 Hz, 1H;19-H).  
13C NMR (100 MHz, Chloroform-d3): δ 207.6, 171.2, 164.3, 164.1, 143.7, 135.7, 125.7, 
107.5, 105.1, 99.8, 77.7, 76.2, 73.6, 72.4, 55.5, 46.2, 37.2, 33.3, 21.7.  
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HRMS (ESI, m/z): Calculated for C19H23O7 [M + H]+ 363.1438; found 363.1433 (1.5 
ppm). 
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Figure 2.17 1H and 13C NMR spectra of compound 2.15 [400 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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Figure 2.18 Major COSY ( ) and HMBC (blue arrows) correlations of compound 2.15. 
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(3aS,5Z,8S,15E,17aS)-11-Hydroxy-13-methoxy-2,2,8-trimethyl-7,8,17,17a-
tetrahydro-4H-benzo[c][1,3]dioxolo[4,5-h][1]oxacyclotetradecine-4,10(3aH)-dione 
(2.16).9  p-Toluenesulfonic acid (2 mg, 0.0116 mmol, 9 mol %) was added to a 
suspension of (5Z)-7-oxozeaenol (2.1) (50.0 mg, 0.138 mmol) in dimethoxypropane (3 
mL) and the mixture stirred for an hour. Dimethoxypropane was evaporated and the 
residue dissolved in CHCl3 (20 mL) and extracted with 10% aqueous NaHCO3 (10 mL). 
The organic layer was dried over anhydrous magnesium sulfate and the solvent 
evaporated. The residue was purified by preparative HPLC using a Phenomenex Gemini-
NX C18 column (250 x 21.20 mm, 110 A, 5 μm spherical particle size). The column was 
perfused at a flow rate of 21.24 mL/min with (water, 0.1% TFA), and a linear gradient 
from 60% to 70% of (CH3CN) over 15 min. The compound eluted at 16.5  min. UPLC 
was used to establish purity using a gradient solvent system that initiated with 20:80 
CH3CN/H2O to 100% CH3CN over 4.5 min; it was >97% pure (Figure 2.3). Yield (23.6 
mg, 43%). 
1H NMR (500 MHz, Chloroform-d3): δ 12.07 (s, 1H; 17-OH), 6.93 (d, J = 15.1 Hz, 1H; 
12-H), 6.36 (s, 2H; 14-H and 16-H), 5.69 (m, 1H; 11-H), 5.37 (bs, 1H; 3-H), 4.58 (m, 1H; 
8-H), 4.55 (m, 1H; 9-H), 3.79 (s, 3H; 20-H), 2.63 (m, 2H; 3-H), 1.57 (s, 3H; 21-H), 1.47 
(d, J = 6.4 Hz, 3H; 19-H). 1.38 (s, 3H; 22-H).  
13C NMR (100 MHz, Chloroform-d3): δ 196.5 (m, 7-C=O), 171.1, 165.6, 163.9, 146.3 
(m; 5-C), 142.6, 133.6, 127.1 (m; 6-C), 126.6, 110.0, 108.9, 103.6, 100.1, 81.7 (m; 8-C), 
77.2, 72.9 (m; 3-C), 55.4, 35.8, 27.0, 25.2 (m; (CH3)2), 19.9 (m; 19-C).  
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HRMS (ESI, m/z): Calculated for C22H27O7 [M + H]+ 403.1751; found 403.1749 (0.6 
ppm).  
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Figure 2.19 1H and 13C NMR spectra of compound 2.16 [500 MHz for 1H and 100 MHz 
for 13C, Chloroform-d3]. 
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Figure 2.20 Major COSY ( ) correlations for compound 2.16. 
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2.3.3 Computational calculations and covalent docking 
2.3.3.1 Ligand preparation 
All calculations were carried out using SPARTAN’08 for Linux. Initial 
conformational analyses were carried out on each ligand using a Monte-Carlo molecular 
mechanics conformational search using the RM1/semi-empirical force field at the ground 
state. All resulting conformations with Erel less than 20 kcal/mol, relative to the  lowest-
energy conformation, were then modeled using Hartree-Fock with the 6-31G* basis set in 
the gas phase. The resulting global minimum was exported to maestro as mol.2 file and 
subjected to covalent docking. 
2.3.3.2 Covalent Docking 
Prior to covalent docking, the crystal structure (PDB ID: 4GS6) was prepared using 
protein preparation wizard, implemented in Maestro, where only hydrogens were added 
to all atoms and bond orders were assigned. The covalent linkage between the 
cocrystallized (5Z)-7-oxozeaenol TAK-1 enzyme was broken, the ligand deleted and the 
bare enzyme used as the binding protein for docking. Covalent docking, implemented in 
Glide, was used to evaluate the relative binding affinities of the various ligands tested.  
The reaction type chosen was Michael addition where amino acid Cycteine 174 was 
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identified as the reactive reside. The grid box was determined as the centroid of residues 
cysteine 174, valine 42 and alanine 46. Cysteine 174 was not chosen as the sole 
determinant of the grid box because it is impeded at the back of the binding pocket thus 
will not result in spanning the biding site efficiently. Many residue combinations were 
screened and the aforementioned collection was representative of a box holding all atoms 
of the co-crystalized (5Z)-7-oxozeaenol in the original crystal structure.  
2.3.3.3 Prime minimization 
The initial covalent docking output with the highest score for each docked ligand 
was minimized using prime, implemented in Maestro. All atoms including those of the 
enzyme and the ligand were minimized using VSGB solvation model. The number of 
iterations implemented for the automatic method of minimization was 8 and the steps per 
iteration were 200. The covalent linkage between the docked ligand and the enzyme, in 
the prime minimization output, was broken and the minimized ligand was covalently 
docked in the minimized enzyme. 
2.3.3.4 TaK1-TaB1 (Transforming Growth Factor-β Activated Linase-1/TAK-1 
Binding Protein 1) Inhibitor Assays 
The assay was performed using Kinase‒Glo Plus luminescence kinase assay kit 
(Promega). It measures kinase activity by quantitating the amount of ATP remaining in 
solution following a kinase reaction. The luminescent signal from the assay is correlated 
with the amount of ATP present and is inversely correlated with the amount of kinase 
activity. Compounds (1‒14) were diluted in 10% DMSO and 5 µL of the dilution was 
added to a 50 µL reaction so that the final concentration of DMSO is 1% in all of 
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reactions. The compounds were preincubated with the enzyme in a reaction mixture for 
10 min at room temperature. The enzymatic reactions were initiated by adding ATP (20 
µM at final) and conducted for 40 min at 30 °C. The 50 µL reaction mixture contained 40 
mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT, 0.2 mg/mL MBP 
substrate, 20 µM ATP and Tak1‒TAB1. After the enzymatic reaction, 50 µL of Kinase‒
Glo Plus Luminescence kinase assay solution (Promega) was added to each reaction, and 
the plate was incubated for 20 min at room temperature. Luminescence signal was 
measured using a BioTek Synergy 2 microplate reader. Tak1‒TAB1 activity assays were 
performed in duplicate at each concentration. The luminescence data were analyzed using 
the computer software, Graphpad Prism. The difference between luminescence intensities 
in the absence of Tak1‒TAB1 (Lut) and in the presence of Tak1‒TAB1 (Luc) was 
defined as 100% activity (Lut – Luc). Using luminescence signal (Lu) in the presence of 
the compound, % activity was calculated as: % activity = [(Lut ‒ Lu)/(Lut ‒ 
Luc)]×100%, where Lu= the luminescence intensity in the presence of the compound. 
The values of % activity versus a series of compound concentrations were then plotted 
using non‒linear regression analysis of Sigmoidal dose‒response curve generated with 
the equation Y=B+(T‒B)/1+10((LogEC50‒X)×Hill Slope), where Y = percent activity, B 
= minimum percent activity, T = maximum percent activity, X = logarithm of compound 
and Hill Slope = slope factor or Hill coefficient. The IC50 values were determined by the 
concentration causing a half‒maximal percent activity. 5Z‒7‒oxozeaenol was used as a 
positive control and showed an IC50 value of 21 nM. 
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2.4 Conclusion 
The importance of TAK-1as a potential target for treating cancer yet the lack of 
clinical candidacy of its most active inhibitor (5Z)-7-Oxozeaenol 2.1 stimulated its 
derivatization via semisynthesis. Seven Analogues were prepared and tested for their 
TAK-1 inhibitory activity along with other structurally-related isolated secondary 
metabolites. The reported activities reconfirmed the necessity of having the Michael 
acceptor and defined part of the scope of allowed structural changes. The implemented 
covalent docking-prime minimization method of the enone-bearing analogues, in hand, 
showed an acceptable level of accuracy in terms of predicting activity. 
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